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ABSTRACT
Pyruvate kinase M2 (PKM2) is a glycolytic enzyme expressed in highly proliferating
cells. Studies of PKM2 have been focused on its function of promoting cell proliferation in
cancer cells. Our laboratory previously discovered that extracellular PKM2 released from cancer
cells promoted angiogenesis by activating endothelial cell proliferation and migration. PKM2
activated endothelial cells through integrin αvβ3. Angiogenesis and myofibroblast differentiation
are key processes during wound healing. In this dissertation, I demonstrate that extracellular
PKM2 released from activated neutrophils promotes angiogenesis and myofibroblast
differentiation during wound healing. PKM2 activates dermal fibroblasts through integrin αvβ3
and PI3K signaling pathway. I also claim that extracellular PKM2 plays a role during liver
fibrosis. PKM2 protects hepatic stellate cells from apoptosis by activating the survival signaling
pathway.
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CHAPTER 1 GENERAL BACKGROUND
1.1

Glycolysis and Pyruvate Kinase
Glycolysis is a process that consumes glucose to provide energy for cells. It is a

sequential process with ten metabolic enzyme reactions. One unit of glucose generates two units
of pyruvate as final product and two units of ATP and NADH as energy resources of glycolysis.
Glycolysis is regulated by several enzymes which form a complex in the cytosol.
Glycolysis is divided into two phases, one is preparatory phase and another one is pay-off
phase. In the preparatory phase, glucose is first converted to glucose-6-phosphate, then to
fructose-6-phosphate, fructose 1, 6-bisphosphate (FBP), and finally to two units of
glyceraldehyde 3-phosphate (GADP). ATP is used in the first and the third step as energy
investment. In the pay-off phase, final product GADP from previous phase is converted into 1, 3bisphosphoglycerate, then 3-phosphoglycerate, 2-phosphoglycerate, phosphoenolpyruvate and
pyruvate as the final product of glycolysis. NADH is generated from the first step and ATP is
generated from the second and the last step. Glycolysis is regulated by three enzymes during the
reaction process, hexokinase, phosphofructokinase, and pyruvate kinase.
Hexokinase is an enzyme functions at the first step of glycolysis. It uses ATP as resource
to phosphorylate glucose and forms glucose-6-phosphate (G6P). When glucose level increases,
hexokinase senses the signal and starts to convert glucose to G6P (Bustamante & Pedersen,
1977). Glucokinase (human hexokinase IV) is one isoform of hexokinases. Due to its unique
ability that its activity is not affected by the production amount, glucokinase can sustainably
produce G6P as the storage of energy if enough glucose is provided (Robey & Hay, 2006).
Phosphofructokinase is an enzyme that catalyzes the irreversible conversion from F6P to FBP. It
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is regulated by ATP concentration, pH level, PEP level, and also AMP level (Wegener &
Krause, 2002).
Pyruvate kinase is an enzyme functions at the last step of glycolysis. It converts
phosphoenolpyruvate (PEP) to pyruvate by transferring one phosphate group from PEP to ADP
and generates ATP. Pyruvate kinase is regulated by ATP and alanine as allosteric inhibitors
(Schulz et al., 1975). FBP acts as an activator for pyruvate kinase that it binds to the pocket on
pyruvate kinase and alternates its conformation to promote the substrate binding (Ashizawa et
al., 1991). Pyruvate kinase deficiency shows slow glycolysis and abnormal metabolism. Severe
metabolism defect is lethal due to extreme low level of ATP (Bowman & Procopio, 1963).
Pyruvate kinase family contains four isoenzymes with tissue dependent expression,
pyruvate kinase L (in liver), pyruvate kinase R (in red blood cells), pyruvate kinase M1 (in
muscle and brain), and pyruvate kinase M2 (in fetal tissue and cancer cells). PKL and PKR are
products of the same gene PKLR locating on chromosome 1 band q21. PKL is a specific isoform
of pyruvate kinase existing in liver. It is also found in kidney, small intestine and pancreas. PKL
is regulated by epinephrine and glucagon through protein kinase A. Upon addition of epinephrine
and glucagon, activated PKA inhibits the pyruvate kinase activity of PKL by adding
phosphorylation (Exton & Park, 1969). PKR is another specific isoform of pyruvate kinase in
erythrocytes. Since erythrocytes are important in oxygen delivering, PKR mutation leads to a
severe disease called chronic nonspherocytic hemolytic anemia (Valentine et al., 1961).
PKM1 and PKM2 are products of PKM gene locating on chromosome 15 on band q22
with different mRNA splicing (Popescu & Cheng, 1990). PKM1 and PKM2 are transcribed from
the same mRNA with alternatively splicing on exon 9 or exon 10 (Noguchi et al., 1986). They
have a forty-five amino acids difference between 389 and 433. Compared with PKM1 expressed
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in normal tissues, PKM2 is mainly expressed in highly proliferative tissues such as cancer cells,
fetal tissues, and immune cells. A study found that c-Myc in cancer cells upregulates the
transcription of heterogeneous nuclear ribonuleoprotein (hnRNP) and polypyrimidine tract
binding protein 1 (PTBP1) to promote inclusion of exon 10 during pre-mRNA splicing in order
to favors cancer cell metabolism (David et al., 2010). The expression of PKM2 is first occurred
during embryonic development, and then it switches to PKM1, PKL, or PKR after fetal
development. During cancer progression, expression of PKM2 is switched back (M. Chen et al.,
2010). The level of PKM2 expression is correlated with cancer progression and metastasis. The
pyruvate kinase activity of PKM2 is lower than PKM1 even with the association of FBP, which
is the allosteric activator of pyruvate kinase.
1.2

Pyruvate Kinase M2

1.2.1 Pyruvate kinase M2 structure and regulation
PKM1 and PKM2 share more than 95% identity in the amino acid sequences because of
the one exon splicing difference. PKM1 forms a tetramer in its native structure. Each monomer
consists of A, B, C, and N four domains. On the other hand, PKM2 is found to have two native
forms. One is the same as PKM1 as a tetramer and another one is a dimer (Dombrauckas et al.,
2005). The tetrameric conformation of pyruvate kinase has higher binding affinity to
phosphoenolpyruvate (PEP), compared with the dimeric form. Therefore, the pyruvate kinase
activity of PKM1 is higher than that of tetrameric PKM2, giving the high affinity of PKM1 to
substrate PEP. In the native structure of PKM2, different amino acid residues locate at the
interface of dimer-dimer PKM2.
As a key kinase in glycolysis, PKM2 is regulated by several factors. FBP, one of the key
activators PKM2, is the intermediate in glycolysis pathway. It is reported that FBP activates the
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association of PKM2 monomer to form tetramer in vitro. After binding to FBP, the active site of
PKM2 is partially closed as a result of the conformational change induced by FBP binding.
PKM2 is also regulated by different phosphorylations. A report found that proviral insertion in
murine lymphomas 2 (PIM2) induces the expression of PKM2 by direct phosphorylation on Thr
454. This threonine residue of PKM2 is critical in cancer cells. Mutation of this residue leads to
glycolysis defect and proliferation reduction (Yu et al., 2013). A study revealed that epidermal
growth factor receptor (EGFR)-activated extracellular signal-regulated kinase 2 (ERK2) interacts
with Ile 429 and Leu 431 of PKM2 and phosphorylates Ser 37 to promote nuclear translocation
of PKM2, which consequently stimulates c-Myc expression. The expression of c-Myc positively
feedback facilitates the PTB-dependent PKM2 expression (W. Yang, Zheng, et al., 2012).
Another study claims that in order to promote Warburg effect and tumor growth, fibroblast
growth factor receptor type 1 (FGFR1), a receptor tyrosine kinase, phosphorylates PKM2 at Tyr
105 to inhibit its tetramer formation through disrupting FBP binding (Hitosugi et al., 2009).
PKM2 is also found to bind phosphotyrosine peptide to promote cancer cell proliferation. The
binding of phosphotyrosine peptides to PKM2 causes the dissociation of FBP which leads to
inhibition of PKM2 activity (Christofk, Vander Heiden, Wu, et al., 2008). In addition, PKM2
mutations have been detected in many disease situations. As an example, PKM2 mutations
(H391Y and K422R) are found in Bloom Syndrome (BS) condition. Co-expression of mutants
H391Y and K422R in cancer cells significantly increased aggressive cancer metabolism, and
tumorigenic potential (Akhtar et al., 2009; Gupta et al., 2010).
1.2.2 Location of pyruvate kinase M2
As a glycolytic enzyme, PKM2 is first discovered in glycolytic enzyme complex. To help
the conversion from PEP to pyruvate and ATP generation, PKM2 locates in the cytosol and
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catalyze the last step of glycolysis. After that, pyruvate is transported to mitochondria for the
following catalysis.
PKM2 is also found in cell nucleus in numbers of studies. A study showed that
interleukin-3 stimulates the nuclear translocation of PKM2 by Jak2 activation, and then promotes
cell proliferation (Hoshino et al., 2007). JMJD5 is induced by hypoxia to stimulate cell
proliferation. Under hypoxia, upregulated JMJD5 binds to PKM2 at the dimer-dimer interface
and inhibits its pyruvate kinase activity. The binding at PKM2 dimer-dimer interface disrupts the
nuclear translocation of PKM2 and promotes hypoxia-inducible factor 1-α (HIF-1-α) mediated
transactivation (Wang et al., 2014). Yang et al. reported that PKM2 presents in cell nucleus to
phosphorylate histone H3 at Thr 11 after EGF receptor activation (W. Yang, Xia, Hawke, et al.,
2012). Our laboratory previously showed that dimeric PKM2 can translocate into cell nucleus.
Nuclear PKM2 activates the transcription activity of MEK5 via phosphorylating stat3 at Tyr 105
(Gao et al., 2012). Compared with activation of proliferation, PKM2 can also translocate into cell
nucleus to induce program cell death (Stetak et al., 2007).
PKM2 has been found extracellularly in several pathological conditions. PKM2 is used as
a serum diagnostic marker in colorectal cancer, lung cancer, gastric cancer, and kidney cancer
(Peng et al., 2011). PKM2 also exists in the stool sample of various cancer patients (Kopylov et
al., 2014). One study claimed that PKM2 is secreted from colon cancer cells and is able to
promote colon cancer cell migration (P. Yang et al., 2014). Our lab found that PKM2 is released
from cancer cells, and extracellular PKM2 can activate endothelial cell migration and
attachment. The level of extracellular PKM2 is also correlated with the progression of severe
immune diseases. PKM2 is used as serum marker for inflammatory bowel disease (IBD) (Jeffery
et al., 2009). Faecal PKM2 is reported to be used as noninvasive marker for ileal pouch
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inflammation (Johnson et al., 2009). Recently, a study discovered that PKM2 level is increased
after retinal rupture laser injury (Paulus et al., 2015).
1.3

Functions of PKM2
PKM2 is expressed during embryonic development. The function of PKM2 in fetal tissue

is still not clear. PKM2 interacts with Oct-4, a key transcription factor in embryonic stem cells,
to promote the transcription activity of Oct-4. The binding of Oct-4 to its target requires PKM2,
possibly C terminal domain of PKM2 (Lee et al., 2008). PKM2 is also expressed in
hematopoietic stem cells. Depletion of PKM2 disadvantages disease development of myeloid
leukemia in mouse model (Zhu et al., 2014).
After fetal development, PKM2 is replaced by other three isozymes, PKM1, PKR, or
PKL. Expression of PKM2 occurs during cancer progression. PKM2 is expressed in all cancer
cells and also some highly proliferating cells, such as immune cells. All pyruvate kinase
isoenzymes form similar tetramer. The pyruvate kinase activity of PKM2 is lower compared with
other isoenzymes because of the low PEP binding affinity of dimer, which can be enhanced by
FBP interaction.
PKM2 functions in several physiological and pathological conditions in addition to its
pyruvate kinase activity in glycolysis. One well-known role of PKM2 in cancer cells is
promoting Warburg effect, which is one of the common features among highly proliferative
cells. As an example, cancer cells prefer to use glycolysis to produce energy but not oxidative
phosphorylation even under the aerobic environment. One explanation of Warburg effect is that
the pyruvate kinase activity of PKM2 is reduced by the conversion from tetramer to dimer. As a
result, the glycolysis process becomes slower at the step of converting PEP to pyruvate due to
the low pyruvate kinase activity of dimeric PKM2. Consequently, the upstream glycolytic
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intermediates are accumulated and converted to the products which are needed for cell
proliferation, such as phospholipids, amino acids and nucleic acids. Therefore, the highly
proliferative cells under Warburg effect condition tend to reduce their aerobic respiration and
focus on the proliferation task (Christofk, Vander Heiden, Harris, et al., 2008; Ferguson &
Rathmell, 2008; W. Yang & Lu, 2013).
PKM2 is also found to act as a sensor to detect insufficiency of glucose. To accomplish
the goal, PKM2 shifts glycolysis to glutaminolysis for ATP production by inactivating itself,
which rescues the cells from glucose starvation induced cell apoptosis. PKM2 involves in the
Raf kinase pathway that α-Raf can activate PKM2 to promote cell proliferation (Le Mellay et al.,
2002; Mazurek et al., 2007). PKM2 also plays a role in the immunological response through
interacting with suppressor of cytokine signaling 3 (SOCS3) and upregulating ATP production
(Z. Zhang et al., 2010). Recently, a group reported that PKM2 translocates into cell nucleus and
regulates gene transcription through interacting with specific gene transcription regulators such
as hypoxia-inducible factors (HIF1) and signal transducer and activator of transcription 3
(STAT3) (W. Yang, Xia, Cao, et al., 2012).
Another characteristic of PKM2 is that it can be secreted by cancer cells. There are high
levels of PKM2 circulating in the blood stream of cancer patients. Serum PKM2 and stool PKM2
are used as cancer markers to prognose various types of cancers. In our laboratory, we
demonstrated that PKM2 was released from cancer cells and human embryonic kidney (HEK)
293 cells. PKM2 in blood circulation promoted tumor growth through stimulation of
angiogenesis. We found that in xenograft tumor mouse model neutralization of PKM2 using
polyclonal antibody against full length PKM2 inhibited the tumor growth compared with the preimmune IgG as the control. We also found that addition of PKM2 to blood circulation can
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promote tumor growth through stimulating angiogenesis. In vitro tube formation assay showed
that the PKM2 treated human umbilical vein endothelial cells (HUVECs) had elevated tube
density and increased tube sprouts number compared with the control cells, suggesting the role
of PKM2 in stimulating angiogenesis. In addition, migration and attachment assays indicated that
extracellular PKM2 promoted endothelial cell migration and attachment. We also found that
integrin αvβ3 was the cell surface target of endothelial cells for PKM2 activated migration,
attachment, and tube formation (L. Li et al., 2014).
1.4

Wound Healing

1.4.1 Wound healing process
Wound healing is a complicated process that organs and tissues repair themselves after
injury. This process consists of numbers of phases in sequence. Wound healing process is mainly
divided into four stages: hemostasis, inflammation, proliferation, and maturation. Hemostasis
happens right after wound induction. Since blood vessel is broken caused by the injury, platelets
move to the broken vessels and aggregate. The main function of platelets at wound site is to clot
blood vessel in order to stop bleeding. To induce aggregation, platelets express glycoproteins on
the plasma membrane to enhance cell-cell attachment. Platelets secrete large amounts of
extracellular matrix, for example fibrin and fibronectin which cross-link together to seal the
broken blood vessels. In addition, platelets also secrete several cytokines and grow factors,
which recruit different types of immune cells to the wound site (Versteeg et al., 2013).
Hemostasis is active for several minutes at the beginning of wound healing. The second
stage is called inflammation that different kinds of immune cells infiltrate into the wound site.
Among them, the first one is polymorphonuclear neutrophil. Neutrophils are recruited by
fibronectin and other growth factors right after hemostasis. In human, neutrophils start to

9

accumulate hours after wound induction, and reach the peak of population at about two days.
Neutrophils kill bacteria by generating free radicals and extracellular traps, and secrete proteases
to clean dead cell debris (Segal, 2005). Neutrophils also release multiple growth factors and
cytokines functioning to trigger the next proliferation stage (Kolaczkowska & Kubes, 2013). The
population of neutrophils declines two or three days after wound induction (Kim et al., 2008).
Apoptotic neutrophils are phagocytized by macrophages, the second population of immune cells
coming to the wound sites after neutrophils. Macrophages cleanse the wound site by
phagocytizing other immune cells, bacteria, and cell debris (Newton et al., 2004). Another
function of macrophage is to facilitate wound healing. After arriving at the wound site and being
activated, macrophages secrete several cytokines and growth factors to stimulate angiogenesis
and granulation tissue growth (Majno, 1998). Macrophages also play a role of anti-angiogenesis
and anti-fibrosis at the late stage of wound repair (Leibovich & Wiseman, 1988).
Towards the end of inflammatory stage, proliferation stage begins that endothelial cells
and fibroblasts are attracted to the wound site under the effect of chemokines and cytokines
secreted by immune cells. Proliferation phase can be divided into two parallel sub phases:
angiogenesis and granulation tissue formation. Angiogenesis is the process that new blood
vessels grow from the pre-existing vessels. It occurs first in order to provide nutrition supply for
proliferation stage. Endothelial cells are attracted by chemoattractant and sprouts out to form
tube structures (Tonnesen et al., 2000). Hypoxia is a factor to stimulate endothelial cell migration
and proliferation that the activated endothelial cells tend to migrate towards the area lack of
oxygen. Endothelial cells also release proteases to digest extracellular matrix in order to migrate
to destination. Granulation tissue formation happens simultaneously along with angiogenesis.
The main source of granulation tissue is fibroblast. Quiescent fibroblasts from adjacent tissue are
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activated by growth factors released from immune cells. They migrate to the wound site and
proliferate rapidly to form the granulation tissue to seal the wound area (Bainbridge, 2013).
While fibroblasts and capillary vessels filling the wound site, fibroblasts also differentiate to
myofibroblasts to help the wound repair. Myofibroblasts secrete large amounts of collagen to
help building up and strengthening granulation tissue. Myofibroblasts also facilitate the
contraction of wound by increase contractile ability of granulation tissue (Grinnell, 1994).
Epithelialization happens throughout inflammation and proliferation stage. Keratinocytes, with
the help of granulation tissue, migrate towards wound center to cover the outside wound area
(Pastar et al., 2014).
The last phase of wound healing is maturation. After wound site is filled up by
granulation tissue, the secretion of collagen is slowed and type III collagen is gradually replaced
by type I collagen, the original collagen in skin. The disordered collagen matrix is rearranged
and cross-linked to form network. Granulation tissue in wound site is converted to the original
skin tissue. Maturation stage is the longest stage in wound healing, which may take several
months depending on the wound size (Teller & White, 2009).
1.4.2 Neutrophil infiltration
Neutrophils are differentiated from myeloid progenitor cells in bone marrow. Inactivated
neutrophils can circulate in the blood flow for several days (Witko-Sarsat et al., 2000). After
activation, neutrophils adhere to blood vessel and infiltrate through in order to migrate toward
the wound tissue (Gonzalez et al., 2007). Activated neutrophils are attracted by the gradient of
cytokines, such as IL-8 and IFN-γ to the wound site (Ellis & Beaman, 2004; Hammond et al.,
1995). Neutrophils act as a double-edged sword during wound repair. If neutrophils are overactivated or neutrophil infiltration is not controlled, tissues will be damaged by the proteases
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released from neutrophils. However, if neutrophils are not present at wound site, spreading of
bacteria will cause infection that strongly slows wound healing time (Smith, 1994). Neutrophils
phagocytize bacteria at the infection site. They release different types of protein through a
process called degranulation. Four types of granules, azurophilic granules (primary granules),
specific granules (secondary granules), tertiary granules, and secretory vesicles are stored in
neutrophils upon activation and released in sequential order after arrival at the infection site. The
primary granules contain most toxic mediators, such as elastase, cathepsins, and defensins. The
secondary granules store lactoferrin and metrix metalloprotease 9 (MMP9) (Borregaard &
Cowland, 1997). Degranulation of neutrophils is activated by fMLP or IL-8 induced GPCR
activation, which sequentially triggers several signal pathways including Rho guanosine
triphosphatase Rac2, β-arrestins, and src family of tyrosine kinases (C. X. Chen et al., 2011). The
activated granules translocate to plasma membrane and fuse with it to release the contents (Lacy,
2006). Activated neutrophils can also release fragments of DNA which contains several
proteases to kill bacteria. The released DNA fragments form web-like structure to trap the
microbes (Brinkmann et al., 2004).
PKM2 is expressed in neutrophils. Activated neutrophils in inflammation diseases had
enhanced pyruvate kinase expression and activity. Several reports have shown that PKM2 could
be used as serum or faecal markers in various inflammatory diseases. For example, pouch
inflammation had increased PKM2 level in stool samples that could be used as indicator.
Mycosis fungoides upregulated PKM2 in blood that plasma PKM2 was considered as potential
marker (Hapa et al., 2011). A recent proteomic study suggested that PKM2 represented in human
neutrophil granules, which provides good evidence of PKM2 release from neutrophils in
inflammatory diseases (Lominadze et al., 2005).
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1.4.3 Angiogenesis
Angiogenesis is the process of generating new blood vessels from existing ones. It is a
sequential and complicated process. Several different types of cells and growth factors are
involved. To start angiogenesis, growth factors and cytokines are released from cancer cells,
embryonic cells fibroblasts, and immune cells. The factors and cytokines then activate the
endothelial cells on the pre-existing vessels through interacting with specific receptors locating
on the cell membrane. Meanwhile, mural cells such as smooth muscle cells and pericytes
dissociate from the blood vessels to leave space for endothelial cells to migrate. The activated
endothelial cells proliferate and sprout out towards the tumor or wound areas to form new vessel
tubes which will be stabilized by mural cells afterwards. During the angiogenesis process,
endothelial cells also release protease to degrade extracellular matrix in favor of their migration
(Risau, 1997).
Angiogenesis is regulated by a variety of pro-angiogenic and anti-angiogenic factors. In
quiescent situation, the two types of factors are balanced to prevent unnecessary angiogenic
effect. When angiogenesis is needed for embryonic development, wound recovering or cancer
progression, pro-angiogenic factors such as vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF), and (platelet-derived growth factor) PDGF, are upregulated that
can cause balance to lean towards pro-angiogenic side, which will initiate the angiogenesis
process (J. Li et al., 2003).
Angiogenesis involves in several physiological and pathological processes, such as
wound healing, tumor growth and metastasis. After blood clot by platelets and clean of wound
site by immune cells, angiogenesis takes place at early stage of proliferation and together with
fibrogenesis to construct granulation tissues to support wound healing process. Capillary vessels
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built through angiogenesis can provide nutrient to fibroblast proliferation and maturation. FGF2
is a 155 amino acids length heparin-binding protein belongs to FGFs family. It regulates
angiogenesis by stimulating proliferation and migration of endothelial cells, smooth muscle cells
and fibroblasts (Powers et al., 2000). FGF2 is widely expressed in the wound area and FGF2 null
mice show delayed healing and thicker scabs when compared with wild-type mice. FGF2 may
play a major role in promoting angiogenesis and granulation tissue formation during wound
healing (Ortega et al., 1998). It is important to have angiogenesis to “feed” granulation tissues
and assist the wound recovering steps. However, the angiogenic effects cannot be overstimulated
at later stage of wound healing. It needs to be shut down for the remodeling process.
In pathological conditions, e.g. cancer progression, angiogenesis functions in two
processes. In process of tumor growth, cancer cells need angiogenesis to recruit blood vessels for
oxygen and nutrient supply. Solid tumor cannot grow beyond 1 mm3 without the support of
blood vessels. To favor tumor growth, cancer cells generate various pro-angiogenic factors to
promote angiogenesis. These pro-angiogenic factors stimulate the angiogenesis through
activating endothelial cell proliferation and migration, and also mural cell dissociation. The
newly divided endothelial cells migrate to the tumor site and form the vessel tubes. Inside the
tumor tissues, blood vessel formation is not well regulated due to genetic errors of cancer cells
and tumor endothelial cells. The disorganization of tumor blood vessel reduces the anti-therapy
efficiency because unregulated vessel network causes resistance to blood flow, which reduces
delivery to all cancer cells. Unregulated vessels also generate local hypoxia in tumor which
continuously activates angiogenesis. In addition, angiogenesis plays an important role in cancer
metastasis. At the late stage of cancer progression, cancer cells gain ability to penetrate to
surrounding tissues to form secondary tumors, or even to invade into the blood vessels and
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circulate with the blood flow to other tissues and organs. Newly formed tumors can stimulate
neovascularization to recruit nutrient supply for rapid growth. Studying angiogenesis in cancer
progression can provide targets for anti-angiogenic therapy to restrain tumor growth in early
stage and prevent metastasis (Bergers & Benjamin, 2003; Weis & Cheresh, 2011).
1.4.4 Myofibroblast differentiation
Fibroblasts differentiate to myofibroblasts during wound healing and tissue repair. The
differentiated myofibroblasts gain high contractile ability to help wound healing process. After
the wound is healed, myofibroblasts undergo apoptosis to prevent excessive stress in the tissue.
If myofibroblast differentiation is not well controlled, it causes fibrotic diseases and supportive
matrix in tumor growth (Eckes et al., 2000).
The differentiation from fibroblast to myofibroblast is divided into two main steps. The
first step is from fibroblast to proto-myofibroblast. Fibroblasts are recruited to the wound site
and acquire minor stress fibers by influence of mechanical force. The second step is from protomyofibroblast to differentiate myofibroblast. Proto-myofibroblasts are activated by growth
factors such as TGFβ to stimulate the expression of α-SMA. α-SMA binds with stress fiber
bundles to further increase contractile activity of myofibroblasts (Hinz et al., 2001; Masur et al.,
1996).
Myofibroblasts have various origins other than fibroblasts. Fibroblasts are the major
resources of myofibroblasts which are attracted to the inflammation site during wound repair.
Pericytes and smooth muscle cells from blood vessels can also be transformed into
myofibroblasts. Fibrocytes generated from bone marrow are found to be another important origin
in the wound case. It is also discovered that fibrocytes take place in fibrosis and tumors to play a
role of myofibroblast differentiation (Baum & Duffy, 2011).
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To identify myofibroblasts, three structural features are important: stress fiber bundles,
high attachment force, and increase cell-cell interaction. α-SMA is the most commonly used
myofibroblast marker. However, α-SMA is also expressed in other cells such as smooth muscle
cells. In addition to the stress features and α-SMA expression in myofibroblasts, induced
extracellular matrix is found in differentiated myofibroblasts. Collagens type I, III, IV, and V are
secreted by differentiated myofibroblasts to build up the matrix network surrounding
myofibroblasts and strengthen the tissue contractile (Hinz, 2007).
The major pathway to activate myofibroblast differentiation is TGFβ-Smad pathway.
TGFβ interacts with to activate TGFβ receptor type II which subsequently recruits TGFβ
receptor type I. Association of TGFβ receptor heterodimer activates its serine/tyrosine kinase
activity, and phosphorylates Smad2/Smad3. Phosphorylated Smad2/Smad3 binds to Smad4 and
translocates into the nucleus to activate α-SMA transcription through interacting with α-SMA
promoters (Engler et al., 2011; Midgley et al., 2013). A few of Smad independent pathway has
been revealed under activation of TGFβ. PI3K is activated by TGFβ signal and transfers the
signal to downstream p21-activated kinase-2 (PAK2), which induces the expression of α-SMA to
promote myofibroblast differentiation (Wilkes et al., 2005; Wilkes et al., 2003). Connective
tissue growth factor and gelectin-3 are cooperatively worked with TGFβ in some circumstances.
Integrin is also found to cooperate with TGFβ receptor in the TGFβ-Smad signal pathway (Ding
et al., 2008; Thannickal et al., 2003). IL-6 and nerve growth factor are discovered to activate
myofibroblast differentiation without the presence of TGFβ, but inhibition of TGFβ signal is not
ruled out in the study (Gallucci et al., 2006). Thus, the independent of TGFβ signal pathway may
still need the downstream of TGFβ pathway.
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1.4.5 From immune response to proliferation
Neutrophils and macrophages are recruited to wound site after injury. They clean bacteria
and damaged cell debris to provide a clean wound for closure. Another important function of
immune cells is to initiate and promote proliferation, including angiogenesis, fibrogenesis and reepithelialization. Neutrophils and macrophages secrete numbers of growth factors and cytokines
to activate endothelial cells and fibroblasts (Barrientos et al., 2008).
Macrophage is considered the major resource of growth factors and cytokines to activate
angiogenesis and fibrogenesis. TGFβ is released from macrophage and activates both
angiogenesis and fibrogenesis during proliferation stage. A chicken chorioallantoic membrane
(CAM) model showed that TGFβ-1 induced the formation of large blood vessels and also
increased fibroblast density. TGFβ-1 activates both proliferation and migration ability of
endothelial cells (E. Y. Yang & Moses, 1990). A study revealed that tumor necrosis factor α
(TNFα) secreted from activated macrophages blood vessel formation in a rat cornea model.
TNFα stimulated chemotaxis of endothelial cells and enhanced tube formation (Leibovich et al.,
1987). Granulocyte/macrophage colony-stimulating factor (GM-CSF) is another growth factor
secreted by macrophages. GM-CSF is found to induce early stage of endothelial tube formation
and late stage of new vessel maturation by regulating VEGF and Ang-Tie expressions (Zhao et
al., 2014).
Functional study of neutrophil during wound repair is mainly focused on antimicroorganism. A group claimed that activated neutrophils increased VEGF expression and
released VEGF to promote angiogenesis (Gong & Koh, 2010). IL-1 and IL-6 are also correlated
with proliferation stage during wound healing. IL-1α and IL-1β upregulated the expression of
keratinocyte growth factor (KGF) in fibroblasts (Tang & Gilchrest, 1996). IL-6 deficient and IL-
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6 antibody treated mice showed delayed wound closure (X. L. Zhang et al., 2005). In addition,
infiltrating neutrophils functioned in tumorigenesis to switch the pro-angiogenesis (Nozawa et
al., 2006). Given the fact that neutrophils arrive at wound site in the early inflammation, they
may play a role of initiating angiogenesis and fibrogenesis during wound repair.
1.4.6 Treatment of wound
For treatment of wound to facilitate repair, different aspects are considered. Collagen
dressings, hydrogels, and growth factors are used to enhance epithelialization. Some drugs are
used to enhance granulation tissue formation. To prevent infection, antimicrobials are always
combined with other drugs in severe wound cases. Several growth factors are released during
wound healing to facilitate the process. Thus, applications of growth factors are proved to have
positive effect on wound healing (Falanga, 2004). Topical application of EGF was first found to
enhance wound healing (Brown et al., 1989). PDGF is also approved by FDA for treatment of
wound (Pierce et al., 1991). However, the application of growth factors is not recommended in
clinical treatment. Different stages of wound are well organized in a sequential order. For each
reaction, it needs to be switched on and off at certain time point. Excessive application of growth
factors may cause prolonged angiogenesis and granulation tissue growth which will inhibit
wound healing by postponing the maturation process.
1.5

Liver fibrosis and cirrhosis

1.5.1 Introduction of liver fibrosis and cirrhosis
Liver fibrosis is characterized by the accumulation of extracellular matrix, especially
collagen in liver. Chronic liver damages induced by alcohol abuse, hepatitis virus, and obesity
are the main causes of liver fibrosis. The accumulated extracellular matrix proteins disrupt the
architecture of liver tissue by forming scar-like network. Advanced liver fibrosis leads to
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cirrhosis which is defined as separation of the hepatocyte nodules by scar tissue. In the late stage
of cirrhosis, scar tissue gradually replaces original liver structure, and finally causes the block of
portal blood flow, and portal hypertension (Bataller & Brenner, 2005; Friedman, 2003).
Liver fibrosis is not easy for diagnosis until development of late stage cirrhosis. Chronic
liver damage takes several years to progress of liver fibrosis to cirrhosis. Cirrhosis is often
correlated with other complications such as ascites, esophageal variceal bleeding, and
hepatocellular carcinoma. Biopsy is the standard method for diagnosis of liver fibrosis. Histology
staining of biopsy can be graded by pathologist in order to identify the stage of liver fibrosis.
Given that collagen expression is the key feature of liver fibrosis, Sirius red staining of biopsy is
another convenient method to identify fibrotic status. However, biopsy is an invasive method
with high error. One time biopsy examination is not suitable for detection of progression of
fibrosis (Thampanitchawong & Piratvisuth, 1999). Serum markers of fibrosis are used as a
noninvasive detection for liver fibrosis. Liver fibrosis patients show high serum level of
aminotransferase, total proteins, collagen, and TIMP-1 (Arthur, 2000). Although serum marker
screening is not invasive method compared with biopsy, it is still not able to identify the
progression of liver fibrosis. Imaging techniques, such as ultrasonography, computed
tomography, and MRI, are also applied in the diagnosis of liver fibrosis due to their
noninvasiveness and good vitalization (Hirata et al., 2001; Popper & Uenfriend, 1970).
1.5.2 Pathogenesis of liver fibrosis
Liver fibrosis starts with inflammation caused by hepatic injury. In regular case,
fibrogenesis starts after hepatic injury and ends when injury is healed, so the inflammatory
response is stopped afterwards. However, in the fibrosis case, the hepatic injury persists
overtime, which leads to prolonged inflammation and subsequent fibrogenesis. Ultimately,
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hepatocytes are replaced with various ECM and eventually the liver fails to heal back. During the
progression of liver fibrosis, ECM accumulation first occurs around portal tracts or
perisinusoidal areas, then elongates to form bridges between the portal tracts, and finally expands
to large area and disrupts liver structure. This is so called frank cirrhosis. Several ECM are
involved in liver fibrosis, including collagens (type I, III, and IV), fibronectin, elastin, laminin,
and proteoglycans. The accumulation of ECM is caused by inhibition of protease such as MMPs,
and activation of TIMPs, specific inhibitors of MMPs.
Hepatic stellate cells (HSCs) are the main player in liver fibrosis development and
progression. In the normal liver, quiescent HSCs reside in liver and function to store vitamin A.
In fibrotic liver, HSCs are activated by different types of factors and migrate to the injury site to
secrete larger amounts of ECM. Platelets are the first cells coming to the injury site. They release
PDGF, TGFβ, and also EGF to activate HSCs including proliferation, migration and
differentiation (Marra, 1999). Activated Kupffer cells at the fibrotic site also secrete large
amounts of cytokines to stimulate HSCs (Naito et al., 2004). Since hepatic injury results in
inflammatory response, infiltrated leukocytes also join with Kupffer cells to activate HSCs.
Neutrophils produce ROS to stimulate the collagen synthesis of HSCs. It was found that coculture of neutrophils with HSCs induced collagen production up to three-fold in vitro. In
addition, several interleukins released by Th1 and Th2 lymphocytes also play a role in HSCs
activation and differentiation. Activated HSCs acquire several behaviors to favor fibrogenesis.
Activated HSCs are attracted by chemoattractants, and their migration activity is upregulated.
ECM production is increased in the activated HSCs. Activation transforms HSCs to
myofibroblasts under stimulation of TGFβ. Induction of collagen expression is the most typical
feature in TGFβ activation of HSCs. On the other hand, ECM degradation is another important
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phenomenon of activation of HSCs. MMPs secreted by HSCs is first upregulated in early stage
of fibrosis to degrade pre-existing ECMs. As long as the fibrosis goes on, the activity of MMPs
is reduced by increase tissue levels of TIMP. Increase in TIMP prevents MMP from degrading
the newly formed ECM network, and maintains progression of fibrosis. Activated HSCs also
acquire high contractile ability due to expression of α-SMA and formation of fiber bundles.
Endthelin-1 is another activator to stimulate contractile ability besides TGFβ (Sato et al., 2003).
1.5.3 Reverse of liver fibrosis
Liver fibrosis and cirrhosis was considered as “irreversible” for many years. However,
more and more experiments and clinical evidences have shown that liver fibrosis and cirrhosis
are reversible. One of the most critical keys in those discoveries is the apoptosis of activated
HSC. One group showed that rats with liver fibrosis induced by CCl4 were able to recover by
removing activated HSCs through apoptosis. Both generator of new ECM and protector of ECM
degradation were eliminated by removal of activated HSCs. The group followed tests with
another model, bile duct ligation, and found that the activated HSCs apoptosis was significantly
enhanced during recovery stage (Benyon & Iredale, 2000; Elsharkawy et al., 2005).
The survival and apoptosis of HSCs is regulated by several mediators. ECM is the main
source to support growth and migration of HSCs. One study suggested that collagen type I
played a role in maintaining the activation of HSCs and mutation of collagen type I resulted in
activated HSCs apoptosis (Bataller & Brenner, 2001). Integrin is also critical for the survival of
HSC. The activated HSCs express integrin αvβ3 on cell membrane. Knockdown integrin αvβ3
by RNAi or inhibition by antibody against the integrin was found to induce HSCs apoptosis
(Iwamoto et al., 1999; Zhou et al., 2004). Several growth factors have been shown to inhibit
HSCs proliferation or induce HSCs apoptosis. Nerve growth factor (NGF) is a growth factor
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secreted by hepatocytes. Treatment of activated HSCs by NGF leads to inhibition of
proliferation. Fas and FasL have been studied for the induction of HSCs apoptosis (Trim et al.,
2000). The activated HSCs have increased expression of both Fas and FasL. Treatment of
activated HSCs with FasL or Fas antibody causes apoptosis in vitro. TNF-related apoptosis –
inducing ligand (TRAIL) is another apoptotic mediating factor of activated HSC. The TRAIL
and TRAIL receptor expression is also upregulated in the activated HSCs in the similar manner
as of Fas and FasL. TRAIL and TRAIL receptor agonists can induce HSCs apoptosis in vitro
(Anan et al., 2006). Nuclear factor kappa B (NF-κB), a well-studied DNA transcription regulator
in several inflammatory events, is involved in the protection of activated HSCs from apoptosis
by upregulating several anti-apoptotic factors including, TRAF-1, TRAF-2, c-IAP1 and c-IAP2.
A study suggested that treatment of NGF induced apoptosis of HSCs and also reduced the
transcriptional activity of NF-κB (Luedde & Schwabe, 2011; Qu et al., 2007; Takahra et al.,
2004). In summary, liver fibrosis and cirrhosis have potential to be reversible. Therapy targeting
activated HSCs apoptosis is proved to be a promising method for treatment of liver fibrosis and
cirrhosis.
1.6

Rational and Aims
Previous studies from our laboratory demonstrated that extracellular PKM2 released from

cancer cells promoted tumor growth through activating angiogenesis. PKM2 promoted tumor
angiogenesis by stimulating endothelial cell proliferation, migration, and adhesion. Angiogenesis
plays an important role in proliferation stage of wound healing. It connects granulation tissue
formation with inflammatory response. Cytokines and growth factors are released from immune
cells during inflammation stage, and then activate angiogenesis. The newly formed vessels
provide blood flow and nutrient supply for growth of granulation tissue. Given that PKM2 is a
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protein expressed and secreted in both cancer cells and neutrophils, and the facts that cancer
progression and wound healing share surprisingly high similarity in many features, it is very
reasonable to hypothesize that PKM2 may play a similar role of promoting angiogenesis in
wound healing. Therefore, we hypothesize that extracellular PKM2 released by neutrophils
promotes angiogenesis to facilitate wound healing process.
In our laboratory, we found that extracellular PKM2 activated endothelial cells via
integrin αvβ3. Fibroblasts upon differentiation have increased expression of integrin αvβ3.
Integrin αvβ3 involves in the myofibroblast differentiation. Given the fact that fibroblasts are the
main source in proliferation stage, it is very likely that extracellular PKM2 at wound site can
stimulate fibroblasts and myofibroblast differentiation through integrin αvβ3.
In our preliminary study of liver fibrosis, we found that the level of extracellular PKM2 is
gradually increased in the liver fibrosis and cirrhosis patients. The expression level of integrin
αvβ3 is correlated with the level of extracellular PKM2. The activated HSCs express high level
of integrin αvβ3 during liver fibrosis. Given that the activation of integrin αvβ3 mediate the
survival pathway, we hypothesizes that extracellular PKM2 released by neutrophils prevents
HSCs from apoptosis, thus worse liver fibrosis.
In this dissertation, the aim is divided into three parts. First, I examine the effect of
extracellular PKM2 during wound healing process. Second, I study the interaction between
PKM2 and fibroblasts in the case of myofibroblast differentiation. Last, I test the function of
extracellular PKM2 against HSCs in liver fibrosis. Here, I demonstrated that topical application
of PKM2 promoted wound healing process through activating angiogenesis. The extracellular
PKM2 at wound site was released from neutrophils under the influence of degranulation. On the
other hand, neutralization of extracellular PKM2 during wound healing inhibited the process. I
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claimed that PKM2 activated myofibroblast differentiation through "αvβ3-PI3K-PAK2"
pathway, which was independent of the classical "TGFβ-Smad" pathway. I also demonstrated
that extracellular PKM2 protected HSCs from apoptosis via integrin αvβ3 survival pathway
during liver fibrosis. Neutralization of extracellular PKM2 during liver fibrosis relieved the
stress of liver fibrosis. Therefore, I established a connection between inflammatory response and
differentiation in physiopathological condition that extracellular PKM2 released from
neutrophils activates endothelial cells and fibroblasts in both wound healing and liver fibrosis.
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Figure 1.1 Locations and functions of PKM2

PKM2 converts PEP to pyruvate in cytosol. PKM2 can translocate in to cell nucleus and
extracellular space. Nuclear PKM2 acts as protein kinase to phosphorylate histone H3 and
STAT3. PKM2 also interacts with transcription factors to induce cell proliferation. Extracellular
PKM2 is used as serum marker for multiple cancers and immune diseases. Cancer cells secrete
PKM2 to promote angiogenesis by activating endothelial cell proliferation and migration.
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Figure 1.2 Wound healing process

Wound healing process is divided into four stages, hemostasis, inflammation, proliferation and
maturation. Each stage is well regulated by different factors in order. The whole wound healing
process takes months to years to heal.

26

Figure 1.3 Liver fibrogenesis

After activation by different stimulators, quiescent HSCs transform into activated HSCs and
secret large amount of extracellular matrix. If this is unsolved and lasts for several years, healthy
liver is damaged and becomes fibrotic. Advanced liver fibrosis develops into cirrhosis, and has
higher incidence of hepatocellular carcinoma.
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CHAPTER 2 EXTRACELLULAR PYRUVATE KINASE M2 RELEASED FROM
NEUTROPHILS FACILITATES EARLY WOUND HEALING BY PROMOTING
ANGIOGENESIS1
1

This chapter was published in Wound Repair and Regeneration.

2.1

Abstract
During wound healing, neutrophil infiltration represents the early inflammation response

to function in cleaning microbes. However, the role of activated neutrophil in tissue regeneration
is still not well understood. Here, we report that the activated neutrophils at wound site release
PKM2 through degranulation at the early stage of wound healing. Extracellular PKM2 facilitates
wound healing by promoting angiogenesis. Our study reveals a new molecular connection
between early inflammation response and proliferation phase in wound repair.
2.2

Introduction
Cutaneous wound healing is a complex process that skin tissue repairs itself after injury.

After wound induction, hemostasis first occurs and broken blood vessels are clotted by platelets.
Different types of immune cells infiltrate into wound site to clean microorganisms and stimulate
the later proliferation stage. Macrophage is considered the major source of activating
angiogenesis, whereas neutrophil mainly plays a role in cleaning microbes and dead cell debris.
However, several studies have showed that the function of infiltrated neutrophil is still
controversial, that neutrophil is found to inhibit re-epithelialization, but also promote
angiogenesis during wound healing (Singer & Clark, 1999).
Pyruvate kinase is an enzyme acts at the last step of glycolysis that converts PEP to
pyruvate to generate ATP. There are four isoforms of pyruvate kinases, L/R and M1/M2. PKM1
and PKM2 are transcribed from the same mRNA with alternative splicing. PKM2 is expressed in

28

highly proliferating cells with low pyruvate kinase activity compared with other pyruvate
kinases. The inactivation of PKM2 slows the process of glycolysis, that more biosynthesis
building blocks are accumulated in favor of cell proliferation. In addition to the role in
glycolysis, PKM2 is involved in other biological processes, such as transcription regulation,
immune response, and metabolism control (Mazurek et al., 2005).
High level of PKM2 is found in the blood stream of cancer patients. Serum and stool
PKM2 levels have been used as diagnostic marker for various cancers. The level of PKM2 in
blood circulation is strongly correlated with progression of cancer (Mazurek, 2007). Our
laboratory previously discovered that extracellular PKM2 promoted tumor growth by activating
angiogenesis. Extracellular PKM2 interacted with integrin αvβ3 on cell surface and stimulated
proliferation and migration of endothelial cells. PKM2 is also detected in the blood stream of
various inflammation diseases. Given that PKM2 is expressed in the immune cells, the function
of extracellular PKM2 might be correlated with inflammation.
2.3

Results

2.3.1 rPKM2 facilitates wound healing by activating angiogenesis.
We previously found that recombinant PKM2 (rPKM2) plays an important role in tumor
angiogenesis. Since angiogenesis is a key stage during wound healing, we first tested the topical
application of rPKM2 mixing with cream in the wound healing CD-1 mouse model. Buffer and
rPKM1 were used as controls. After wound induction, the size of wound was measured on day 0,
day 3, day 6, and day 8 (Figure 2.1 A). The quantitative curve showed that rPKM2 group had
smaller wound area on day 3 and day 6 compared with rPKM1 and buffer groups. The
differences among three groups were not significant on day 8 (Figure 2.1 B). From skin wound
pictures, the wound size was smaller in rPKM2 group, compared with rPKM1 and buffer groups
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on day 3. The difference was more significant on day 6. The wound size in all groups on day 8
looked similar (Figure 2.1 C). In a word, topical application of rPKM2 facilitates wound healing
process.
To test the angiogenic effect during wound healing, skin tissue at wound site was stained
with CD-31 (endothelial cell marker) using immunofluorescence staining. rPKM2 group showed
more condensed signal compared with the staining in rPKM1 and buffer groups (Figure 2.2 A).
To quantify the immunofluorescence staining, we analyzed the micro vesicular density (MVD)
and the area covered by CD31 positive staining. rPKM2 group showed significant increase in
both MVD and CD31 positive area (Figure 2.2 B&C). As a result, topical application of rPKM2
promotes wound healing by activating angiogenesis.
2.3.2 rPKM2 promotes granulation tissue growth during wound healing
Angiogenesis and the growth of granulation tissue are strongly connected with the
proliferation stage of wound healing. Since topical application of rPKM2 promotes angiogenesis,
we pursued the effect of rPKM2 on the growth of granulation tissue. Granulation tissue is formed
during the proliferation stage of wound healing. It consists of connective tissue and capillary
networks that build up from the bottom of the wound and fill the whole wounded area. It also
protects the wound from further infection. After proliferation stage, granulation tissue gradually
remodels to normal skin or tissue. It is important to have the proper granulation tissue growth
during wound healing. The growth of granulation tissue at early time of wound healing indicates
a start of the proliferation stage. By measuring the thickness of granulation tissue (distance from
bottom to top of the granulation tissue), we can analyze the process of wound healing, and how
the wound is healed.
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We first examined the inner side of wound skin. rPKM2 group had complex capillary
structure and thick granulation tissue, whereas rPKM1 and buffer groups had thin granulation
tissue, or even transparent membrane structure (Figure 2.3 A). To quantify the thickness of
granulation tissue, the slides with vertical cut were stained by H&E staining. The thickness of
granulation tissue was measured from the outside to the inside of wound skin. As a result, the
thickness of granulation started to increase as early as day 3 in rPKM2 group. This effect
continuously maintained till the end of the experiment (Figure 2.3 B). To further analyze the
growth of granulation tissue, fibroblast was stained in the frozen section of wound skin using
fibroblast marker (ER-TR7). rPKM2 group had more condensed fibroblast signal compared with
rPKM1 and buffer groups. The quantified result showed that the fibroblast positive area was
doubled in rPKM2 group (Figure 2.3 C). In summary, Topical application of rPKM2 stimulates
the growth of granulation tissue during wound healing.
2.3.3 Application of PKM2 antibody slows wound healing process
Given the effect of rPKM2 during mouse cutaneous wound healing, we generated a new
mouse wound healing model using PKM2 antibody to neutralize extracellular PKM2 during
wound healing. Buffer and IgGCon were used as controls. The rabbit monoclonal PKM2
antibody was first I.P. injected into CD-1 mice one day before wound induction to let it circulate
in the blood system. The following procedure was similar as in the previous wound healing
experiment (Figure 2.4 A&B). The healing speed of wound was slower in IgGPK group
compared with buffer and IgGCon groups (Figure 2.4 C). From the quantitative curve, IgGCon
and buffer groups were at the same trend, compared with IgGPK group with a slow start from
day 2. This inhibition effect continued till day 8 (Figure 2.4 B).
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To determine the effect of PKM2 antibody in angiogenesis, we performed the same
CD31 staining and quantified with MVD and CD31 positive area. We clearly saw the capillary
structure in buffer and IgG groups, even tube structure in buffer group. The density and length of
vessels were significantly decreased in IgGPK group. The quantified data showed that both
MVD and CD31 positive area were reduced under the treatment of PKM2 antibody (Figure 2.5
B&C).
2.3.4 PKM2 was released from neutrophils in wound healing
To find out whether PKM2 is endogenous in wound healing, we collected the skin
samples on day 3 of wound healing in both rPKM2 treated and non-rPKM2 treated groups.
Samples were paraffin embedded and stained with PKM2 antibody for IHC. The non-wound
tissue did not have any positive signal of PKM2. In wound tissue, compared with rPKM2 treated
sample, non-rPKM2 treated one had light signal of PKM2 positive staining (Figure 2.6 A). This
indicated that PKM2 was endogenous during wound healing. In cancer progression, PKM2 is
secreted by cancer cells and locates in the extracellular space. After observation under higher
magnification, we found that most PKM2 located in the extracellular space (Figure 2.6 B). The
cells containing intracellular PKM2 had similar polymorphonuclear phenomenon like
neutrophils. We suspected that neutrophils are the resource of extracellular PKM2 during wound
healing. To test the correlation between extracellular PKM2 and neutrophils, we generated a
time-series wound skin samples from day 0 to day 5 and stained the samples with PKM2 and
Ly6G antibody (neutrophil marker). By quantifying the positive signal in each staining, we
observed a similar pattern of increase and decrease in PKM2 and Ly6G staining (Figure 2.6
C&D). This meant that the presence of neutrophils is highly correlated with extracellular PKM2.
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We used in vitro system to study the release of PKM2 from neutrophils. Neutrophils were
isolated from mouse bone marrow and activated with fMLP and damnacanthal for 15 min. Both
culture medium and cell lysates were collected for immunoblot. The medium PKM2 level was
increased in the fMLP and damnacanthal treatments (Figure 2.7 A&B). We also obtained a
sucrose gradient sample of neutrophil fractionation from Dr. Yuan Liu's lab. Two sets of
samples, inactivated neutrophils and fMLP activated neutrophils were examined by immunoblot
using PKM2, β-actin (represents cytosolic part) and CD11b (represents granule part) antibodies.
In the inactivated neutrophils, PKM2 located in the cytosol as β-actin. In the fMLP activated
neutrophils, PKM2 had another fraction in granules as CD11b. In summary, we revealed that
PKM2 is released from activated neutrophils.
2.3.5 Inhibition of neutrophil infiltration reduces extracellular PKM2
To further test the correlation between extracellular PKM2 and neutrophils, we used
beige-J mouse, a mouse strain with neutrophil infiltration defect, as the model in wound healing
study. At day 3 after wound induction, wild-type group had reduced wound size compared with
beige group (Figure 2.8 A). On the other hand, wild-type group had thicker granulation tissue
(Figure 2.8 B). IHC staining of wound sites showed that wild-type group had both Ly6G and
PKM2 positive signals, but beige group had no signal (Figure 2.8 C). This indicated that beige-J
mice had reduced extracellular PKM2 at wound site as a result of defective neutrophil
infiltration. To further confirm the correlation between extracellular PKM2 and neutrophils, we
also applied rPKM2 to the wound of beige-J mouse to test whether this application can overcome
the defect. Reasonably, rPKM2 application increased the speed of wound healing, but it was still
slower compared with wild-type mouse (Figure 2.8 D).
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2.3.6 Identification of PKM2 release from neutrophil degranulation
To test whether degranulation is the way to release PKM2, we used several degranulation
inhibitors. PP1, SB 203580, and piceatannol were pre-treated before fMLP activation. Compared
with fMLP activation of PKM2 level in the culture medium, the inhibitors treated ones had
different degrees of reduction. Piceatannol had the best inhibitory effect among three inhibitors
(Figure 2.9 A). We also examined the time-series of fMLP activation in PKM2 release. We
picked up 5 min, 10 min, and 30 min to test the level of released PKM2 in the culture medium,
which showed gradually increasing (Figure 2.9 B&C). In summary, in vitro cell analysis
demonstrated that PKM2 is released by neutrophils through degranulation.
2.4

Discussion
Wound healing is a slow and complex process. Opened wound area causes several

infection problems. To prevent infection and seal wound at an early time is the major goal of fast
wound healing. Different immune cells function in cleaning microorganisms and promoting
granulation tissue formation. A major question in wound healing process is what is role of
immune cells during the early stage of wound healing. Here we found that neutrophils as the
early resources of immune cells release PKM2 to facilitate granulation stage of wound healing. It
fills a gap between early inflammation and proliferation stage. We demonstrated that PKM2 is
released from neutrophils via degranulation process. The extracellular PKM2 activates
angiogenesis and promotes the growth of granulation tissue in proliferation stage. We followed
up to use PKM2 antibody to inhibit the connection between neutrophil infiltration and
granulation tissue growth. The wound healing was significantly slowed and the angiogenic effect
was reduced.
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Another question is why and how neutrophils release PKM2. Neutrophil is one of the
earliest immune cells arrive at wound site. Neutrophil infiltration reaches to a peak around 48 to
72 hours in mouse cutaneous wound. High density of neutrophils accumulates at wound site and
release large amount of PKM2 to stimulate angiogenic activity. The induced angiogenesis
supports the later coming fibroblasts to build up granulation tissue. Extracellular PKM2 plays an
important role in early wound healing process as the connection between inflammation and
proliferation stage. Neutrophils have several secretory pathways for protein transportation. Since
PKM2 is a cytosolic protein, the classic secretory pathway which needs membrane recognition
peptide is not the proper transporting method. Our experiments showed that the release of PKM2
was highly correlated with degranulation. PKM2 level was gradually increased in the culture
medium of activated neutrophils and was significantly reduced under the effect of degranulation
inhibitors. We thought PKM2 in cytosol was interacted with the protein in or on the granules and
was coupled transported out of the cells during degranulation.
2.5

Materials and Methods

2.5.1 Mouse Wound Healing Model
All animal experiments were carried out in accordance with the guidelines of IACUC of
Georgia State University. CD-1 mice were anesthetized with 3% isoflurane and kept under
anesthesia during the whole surgery process. The furs on back of mice were shaved with
electronic hair shaver and further cleared with Nair (Church & Dwight Co Inc.). The shaved
areas were cleaned and aseptically prepared with cotton swabs soaking in antiseptic surgical
scrub solution and 70% alcohol alternatively for three times. The body temperature of mouse
was maintained by using a circulating water bed. The surgical areas were kept sterile throughout
the surgery process. The wounds were induced by using a 6 mm diameter dermatology biopsy
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punch. The photo of wound was taken and the size was measured by caliper. Vanicream (Stacy's
Compounding Pharmacy) mixed with buffer, rPKM1 or rPKM2 was applied on the wound. The
wounds were then dressed with transparent adhesive films, and wrapped with adhesive tapes.
The mice were carefully monitored during surgery and 30 min after, and then single housed to
prevent scratching. The wounds were re-opened and same procedure of cream application and
dressing were performed on day 3, day 6. The mice were euthanized on day 8 by CO2. Skin
wound samples were collected and put in frozen section or paraffin embedded. The slides were
cut vertically across the wound area.
2.5.2 Tissue Sample Preparation
The wounded areas were cut off for sample preparation. For the frozen tissue, the
samples were immersed in the OCT solution and snap-frozen in liquid nitrogen. The frozen
section slides were cut with cryostat. For paraffin embedding tissue, the samples were incubated
in the formalin solution at room temperature for two days, and then stored at 4 ˚C in 70%
ethanol. The paraffin embedding process was done by using Citadel with the standard protocol,
and then embedded with Histostar. The paraffin embedding section slides were cut with
microtome.
2.5.3 H&E Staining
The paraffin slides were baked at 60 ˚C for 2 hours, and then incubated with the
following solutions 5 min each in order (three times xylene, twice 100% ethanol, 90% ethanol,
70% ethanol, 50% ethanol, 30% ethanol, and distilled water). The slides were incubated with
0.1% Mayers Hematoxylin for 5 min and washed with running water. The slides were dipped in
0.5% Eosin for 1 min and then washed with water. The slides were dehydrated by incubated with
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the previous solutions reversely. At last, the slides were mounted with mounting medium and
covered by coverslip. The coverslips were sealed with nail polish and waited for one day to dry.
2.5.4 Measurement of Granulation Thickness
The pictures shown in the figure were taken by camera. The wound skin samples were
cut off and flipped over. The H&E staining slides from buffer and rPKM2 group at different time
points were observed under microscope. The distance between out-layer and inner-layer of skin
was measured for each slide. All results were averaged and normalized with the result of buffer
group on day 3.
2.5.5 Neutrophil Isolation
CD-1 mice were killed, and the femur and tibia were removed and cleaned. HBSS-EDTA
was injected through the bone to push out cell clumps. The cells were washed once with HBSS,
laid on a three-layer Percoll gradient (78%, 69%, and 52% from bottom to top), and then
centrifuged at 1500 g for 30 min. The upper part of 78% and interface between 78% and 69%
were collected and washed twice with HBSS-EDTA. The cells were resuspended in HBSSEDTA for later experiment.
2.5.6 Activation of Neutrophils
To evaluate the release of PKM2 to culture medium, isolated neutrophils were treated
with 1 μM fMLP at 37 ˚C for 20 min or 1 μM damnacanthal at 25 ˚C for 20 min in HBSS, and
then centrifuged to collect the medium for following ELISA and Western blot. Cell pellets were
lysed with RIPA buffer for the analysis of cytosol components. For the inhibitor assay, cells
were pretreated with PP1 (10 μM), SB 203580 (1 μM), and piceatannol (20 μM) for 15 min,
followed by same fMLP stimulating procedure. For the time series assay, cells were treated with
1 μM fMLP at 37 ˚C for 5, 10, and 30 min, respectively.
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2.5.7 Beige Mice Wound Healing Protocol
The beige mutant and wildtype mice were purchased from The Jackson Laboratory. The
wound was generated same as in the CD-1 mice previously. Generally, mice were anesthetized
and kept under anesthesia during the whole surgical procedure. The furs on back of mice were
shaved and the surgical site on mouse back was cleaned and aseptically prepared. The wounds
were induced by using a 6 mm diameter dermatology biopsy punch, and then dressed with
transparent adhesive film (3M), and wrapped with adhesive tape. The mice were euthanized on
day 3, and the wounded skins were cut off and processed for paraffin embedding.
2.5.8 Sucrose Gradient Centrifugation
Freshly isolated neutrophils were lysed and loaded onto a prepared sucrose gradient from
50% at bottom to 20% at top. After centrifugation at 66000 x g for 90 min, fractions were
collected and prepared for immunoblot.
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Figure 2.1 Topical application of rPKM2 facilitates wound healing.
(A). Diagram of mouse wound healing experiment. Cutaneous wounds were induced on the back
of three groups of mice on day 0, and applied with cream mixing buffer, rPKM1, and rPKM2
respectively. The cream mixing with reagent was re-applied on day 3 and day 6. All mice were
euthanized on day 8. (B). Quantitative analysis of wound size. Wound size was measured on day
0, day 3, day 6, and day 8. The size of day 0 was set as 100%, and gradually reduced by healing.
(C). Pictures of wound. Pictures were taken by camera on day 0, day 3, day 6, and day 8.
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Figure 2.1 Topical application of rPKM2 facilitates wound healing.
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Figure 2.2 Topical application of rPKM2 activates angiogenesis during wound healing.
(A). Immunofluorescence staining of CD31. Wound skin samples were cut off and snap-froze in
opti medium in liquid nitrogen. Frozen sections were cut vertically through the wound area.
CD31 was stained in green and DAPI was in blue. (B). Quantification of CD31 staining.
Quantification was processed by ImageJ. Microvescular density was quantified by counting each
staining pattern. CD31 positive pixel was quantified by calculating the area of CD31 staining.
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Figure 2.2 Topical application of rPKM2 activates angiogenesis during wound healing.
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Figure 2.3 Topical application of rPKM2 induces granulation tissue growth during wound
healing.
(A). Pictures of inner side of wounded skin. The wounded skin was cut off at day 8. The pictures
were taken after flipping and spreading the wounded skin. (B). Quantification of thickness of
granulation tissue. The wounded skin was cut off at day 3, day 6, and day 8, and embedded in
paraffin for vertical sliding. The slides were performed with H&E staining. The thickness was
measured by the length from the outside to the inside of wounded skin on H&E stained slide.
The measurements were averaged and compared between buffer and rPKM2 groups. (C).
Immunofluorescence staining of fibroblast and quantification. The fibroblast was stained in
green with fibroblast marker ER-TR7, and DAPI was in blue. Quantification was processed by
ImageJ. ER-TR7 positive pixel was quantified by calculating the area of staining.
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Figure 2.3 Topical application of rPKM2 induces granulation tissue growth during
wound healing.
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Figure 2.4 Neutralization of extracellular PKM2 inhibits wound healing process.
(A). Diagram of mouse wound healing experiment. Cutaneous wounds were induced on the back
of three groups of mice on day 0, and applied with cream mixing buffer, IgGCon, and IgGPK
respectively. The cream was re-applied on day 2 and day 4. All mice were euthanized on day 8.
(B). SDS-PAGE of antibody pair, IgGCon vs IgGPK. Immunoblot of IgGPK on whole cell
lysate of SW480 cell. (C). Quantitative analysis of wound size. Wound size was measured on
day 0, day 2, day 4, day 6, and day 8. The size of day 0 was set as 100%, and gradually reduced
by healing. (D). Pictures of wound. Pictures were taken by camera on day 0, day 2, day 4, day 6,
and day 8.
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Figure 2.4 Neutralization of extracellular PKM2 inhibits wound healing process.
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Figure 2.5 Neutralization of extracellular PKM2 reduces angiogenesis.
(A). Immunofluorescence staining of CD31. Wound skin samples were cut off and snap-froze in
opti medium in liquid nitrogen. Slides were cut vertically through the wound area. CD31 was
stained in green and DAPI was in blue. (B). Quantification of CD31 staining. Quantification was
processed by ImageJ. Microvescular density was quantified by counting each staining pattern.
CD31 positive pixel was quantified by calculating the area of CD31 staining.
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Figure 2.5 Neutralization of extracellular PKM2 reduces angiogenesis.
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Figure 2.6 Identification of extracellular PKM2 in wound healing.
(A). Immunohistochemistry staining of PKM2 in wounded skin samples. Wounded skin at day 2
were cut and embedded in paraffin. Samples were cut vertically and stained with PKM2 antibody.
The results were compared between non-wound tissue, wound tissue and wound tissue treated
with rPKM2. (B). Identification of extracellular PKM2 in 10X and 40X magnification. (C). Time
series of PKM2 and Ly6G staining. Mouse wounded skin samples from day 0 to day 5 were cut
and embedded in paraffin. Samples were cut vertically and stained with PKM2 or Ly6G
respectively. (D). Quantification of time series of PKM2 and Ly6G staining. Quantification was
processed by FRamework for Image Dataset Analysis (FRIDA).
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Figure 2.6 Identification of extracellular PKM2 in wound healing.
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Figure 2.7 In vitro analysis of extracellular PKM2 released by neutrophils.
(A). Release of PKM2 by neutrophils under degranulation stimulation. Neutrophils were isolated
from mouse bone marrow and activated with fMLP and damnacanthal. Whole cell lysate and
concentrated culture media were analyzed by Western blot using PKM2 and β-actin antibody.
(B). Quantification of released PKM2 by ELISA. Isolation and activation of neutrophils were
performed the same as in Western blot. Culture media were added into ELISA plate coated with
PKM2 antibody. Level of released PKM2 was measured with another PKM2 antibody and then
recorded by spectrophotometer. (C). Presence of PKM2 in sucrose gradient fractions of activated
neutrophils. Sucrose gradient fractions of neutrophils were analyzed with PKM2, β-actin, and
CD11b antibodies using Western blot.
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Figure 2.7 In vitro analysis of extracellular PKM2 released by neutrophils.
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Figure 2.8 Identification of extracellular PKM2 in wounded beige-J mouse.
(A).Wound size comparison between beige and WT mice at day 3. Wound was induced the
same as in CD-1 mice. (B). Granulation in beige and WT mice at day 3. Wounded skin was cut
off and processed with H&E staining to measure the thickness of granulation. (C).
Representative images of IHC staining of wound tissue sections from beige-J and WT mice.
Wound skin tissue was collected at day 3.
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Figure 2.8 Identification of extracellular PKM2 in wounded beige-J mouse.

54

Figure 2.9 Inhibition and time series of extracellular PKM2 released from neutrophils.
(A). Inhibition of PKM2 release by degranulation inhibitors. Neutrophils were isolated and
activated by fMLP. PP1, SB 203580, and piceatannol were tested under fMLP stimulation.
Whole cell lysate and culture media were analyzed using Western blot. (B). Time series of
PKM2 release in neutrophils. Neutrophils were activated by fMLP and culture media were
collected at different time points for Western blot analysis. (C). Quantification of time series
released PKM2 by ELISA. Culture media were added into ELISA plate coated with PKM2
antibody. The level of released PKM2 was measured with another PKM2 antibody and then
recorded by spectrophotometer.
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Figure 2.9 Inhibition and time series of extracellular PKM2 released from neutrophils.
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CHAPTER 3 EXTRACELLULAR PYRUVATE KINASE M2 ACTIVATES DERMAL
MYOFIBROBLAST DIFFERENTIATION
3.1

Abstract
Extracellular PKM2 released from neutrophils promotes wound healing by activating

angiogenesis. In addition, we claim that extracellular PKM2 can also activate dermal fibroblasts
to undergo myofibroblast differentiation. PKM2 facilitates the formation of early granulates at
wound site by promoting fibroblast migration and myofibroblast differentiation. We demonstrate
that extracellular PKM2 promotes myofibroblast differentiation through a TGFβ independent
pathway via activation of integrin αvβ3 signaling. Our studies discover another function of
extracellular PKM2 during wound healing to link early inflammation response with proliferation
stage. Our studies also uncover a novel mechanism of stimulating myofibroblast differentiation.
3.2

Introduction
Myofibroblast differentiation is a key process during the proliferation stage of wound

healing. Fibroblasts are recruited to the wound site by growth factors and cytokines released
from immune cells. Together with endothelial cells, fibroblasts build up the granulation tissue to
fill up wound area. After wound closure, fibroblasts convert to myofibroblasts to further contract
the wound and secret extracellular matrix to support wound repair (Hinz, 2007).
TGFβ is the major ligand to activate myofibroblast differentiation. TGFβ activates TGFβ
receptor on the plasma membrane fibroblasts. The activated TGFβ receptor heterodimer
phosphorylates Smad complex to induce the nuclear translocation of Smad complex that leads to
the upregulation of several fibroblast differentiated gene transcription, including α-SMA.
Integrin αvβ3 also involved in myofibroblast differentiation (Gressner et al., 2002). Previously
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we found that extracellular PKM2 promotes endothelial cells migration and attachment through
integrin αvβ3.
3.3

Results

3.3.1 Myofibroblast differentiation is activated in rPKM2 treated wound
After examining the inside of wounded skin, we found that granulation tissue was grown
much thicker in rPKM2 group. We questioned whether other effects of extracellular PKM2
existed besides activation of endothelial cells. Given that both endothelial cells and fibroblasts
have integrin αvβ3 expression, we hypothesized that extracellular PKM2 also activated dermal
fibroblasts during wound healing. We first checked myofibroblast differentiation in the wound
skin sample. Frozen sections were stained with α-SMA antibody via immunofluorescence
staining. The rPKM2 treated mice had increased level of α-SMA at wound site (Figure 3.1
A&B). Three time points as in granulation tissue thickness measurement were picked up for
staining of α-SMA expression. On day 3, day6, and day 8, the rPKM2 treated mice all showed
elevated levels of α-SMA (Figure 3.1 C). The PKM2 antibody treated group was also tested and
the α-SMA level was reduced (Figure 3.1 D). Since other type of cells in skin also had αvβ3
expression, such as smooth muscle cells. To exclude the possibility of smooth muscle cells and
also confirm the fibroblast staining, frozen sections were co-stained by α-SMA and smooth
muscle cell marker myosin or fibroblast marker ER-TR7. Myosin and α-SMA had different
staining pattern, on the other hand, ER-TR7 staining was overlapped with α-SMA expression
pattern (Figure 3.2 A). In summary, myofibroblast differentiation is activated in the PKM2
treated mice during wound healing.
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3.3.2 Effect of extracellular PKM2 on HDFa
To test the effect of PKM2 on fibroblasts, human dermal fibroblasts adult (HDFa) were
treated with rPKM2 and tested in proliferation and migration assays. In BrdU proliferation assay,
rPKM2 treated HDFa had a little bit increase compared with the controls, but it was not
significant (Figure 3.2 B). In boydem chamber assay, rPKM2 treated cells had three-fold
increase compared with the controls (Figure 3.2 C). After 48 hours of rPKM2 treatment, HDFa
cells had increased expression of α-SMA in the immunoblot test. It was slightly less compared
with the TGFβ treatment. Combination of rPKM2 and TGFβ treatment had enhanced α-SMA
expression (Figure 3.3 A). To detect the differentiating features, HDFa were treated with rPKM2
or TGFβ, and then stained with phalloidin, α-SMA, and DAPI. HDFa cells in buffer group still
remained the spindle shape, and the expression level of α-SMA was low. Both rPKM2 and TGFβ
treated cells had the typical myofibroblast spreading shape and the signal α-SMA expression was
stronger. Actin (Red) and α-SMA (green) formed bundles in yellow. In rPKM2 group, HDFa
cells had more protrusions structures (Figure 3.3 B). Collagen level in culture medium was also
increased in rPKM2 and TGFβ treated cells (Figure 3.3 C).
3.3.3 Extracellular PKM2 activates HDFa cells through integrin αvβ3
In the previous study, we found that extracellular PKM2 activates endothelial cells
through integrin αvβ3 signaling. Since HDFa also have integrin αvβ3 on the cell surface, we
questioned whether it was the same cell surface receptor on HDFa for extracellular PKM2. First,
in vitro cell attachment assay was used to test the interaction between integrin αvβ3 and PKM2.
HDFa only attached on rPKM2 coated plate and this effect was eliminated by the pretreatment of
αvβ3 antibody (Figure 3.4 A). We carried out chemical crosslinking with rPKM2 and the
membrane extracts of HDFa using glutaraldehyde as a crosslinker. The crosslinked proteins were
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separated by His-tag pull-down and subsequently digested by trypsin. The digested integrin αvβ3
peptides were found in the mass spectrometry result (Figure 3.4 C). To further confirm the
interaction between PKM2 and integrin αvβ3, we also tested the pull-down assay by PKM2
antibody and control antibody in western blot. Integrin β3 was detected in PKM2 antibody
group, but not in control antibody group (Figure 3.4 B). Furthermore, in the migration activity
assay, the αvβ3 antibody reduced the level of migration down to the buffer level (Figure 3.4 D).
TGFβ pathway is the well-known pathway to activate myofibroblast differentiation. We
then asked whether PKM2-αvβ3 signaling was independent of TGFβ signaling pathway. Two
additional treatments were used. TGFβ antibody was pretreated to neutralize the possible TGFβ
residue in culture medium, and TGFβ receptor inhibitor was used to block TGFβ signaling
pathway. Both of them were added into rPKM2 and TGFβ treatments respectively. As shown in
the immunoblot, rPKM2 or TGFβ treatments induced the expression of α-SMA. PhosphoSmad2, the downstream signal of TGFβ signaling, was activated in TGFβ treatment, but not in
rPKM2 treatment. Upon addition of TGFβ antibody or TGFβ receptor inhibitor, both α-SMA and
p-Smad2 signal were lost in TGFβ treated cells. However, rPKM2 treatment was still able to
induce α-SMA expression (Figure 3.5 A). Since PKM2 interacts with integrin αvβ3 on the cell
surface of HDFa, we pretreated integrin αvβ3 antibody and the expression of α-SMA was
reduced (Figure 3.5 B). FAK activation is the major downstream target of integrin αvβ3. If
extracellular PKM2 activates HDFa through integrin αvβ3, then FAK should be activated.
Phospho-FAK was detected as the signal of FAK activation. The rPKM2 treatment stimulated
both expression α-SMA and phosphorylation of FAK, which were abolished after the treatment
of FAK inhibitor (Figure 3.5 C).
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Then we questioned what the downstream signal pathway of PKM2-αvβ3-FAK was. We
first screened with several FAK downstream pathway inhibitors. PI3K, Src, and MEK inhibitors
were applied and PI3K inhibitor showed the strongest inhibition in α-SMA expression (Figure
3.6 A). To further confirm this effect, we tested PI3K activity with treatment of rPKM2. Buffer
treatment was normalized to baseline, and rPKM2 treatment had three-fold increase with or
without addition of TGFβ receptor inhibitor. In addition, pretreatment of FAK inhibitor brought
PI3K activity down to the baseline level (Figure 3.6 B). It is reported that PAK2 is activated by
PI3K and plays a role in myofibroblast differentiation. We followed this track to test activation
of PAK2 with the treatment of rPKM2. The rPKM2 treated HDFa cells stimulated the
phosphorylation of PAK2 compared with rPKM1 and buffer controls (Figure 3.6 C).
3.4

Discussion
Myofibroblast differentiation is a critical pathophysiology process involved in different

circumstances, including wound healing and fibrosis. We first noticed the granulation tissue was
very thick in the previous wound healing experiment. Only by angiogenesis is not enough to
grow such level of granulation tissue. Given the similar features between endothelial cells and
fibroblasts, we tested the effect of extracellular PKM2 on dermal fibroblasts. Extracellular
PKM2 activated the differentiation of myofibroblast through integrin αvβ3 and PI3K signaling
pathway during wound healing.
One question is why extracellular PKM2 is the stimulator in addition to TGFβ. TGFβ is
the well-known major growth factor to activate myofibroblast differentiation via Smad family
signaling pathway. We found that rPKM2 activated dermal fibroblasts independent of TGFβ
through integrin αvβ3. It is reported that only TGFβ is not enough to transit quiescent fibroblast
to myofibroblast and TGFβ activation can change the transcription profile of fibroblast, such as
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increase of integrin αvβ3 expression level. Thus, during wound healing, fibroblasts are attracted
to wound area and activated by TGFβ first. After the increase of integrin αvβ3 level,
extracellular PKM2 further converts myofibroblast differentiation. That was why the
combination of rPKM2 and TGFβ had the strongest effect in α-SMA stimulation.
3.5

Materials and Methods

3.5.1 Induction of HDFa Differentiation
HDFa were cultured to reach 70% confluency, and starved with serum-free medium
overnight before differentiation induction. The cells were treated with TGF-β (10 ng/mL) or
rPKM2 (0.1 µM) for 2 days. After treatment, the cells were lysed with RIPA buffer and medium
was collected for further analysis. Cell lysates prepared with RIPA buffer and culture media
were collected and analyzed with western blot.
3.5.2 Cells Immunofluorescence Staining
HDFa seeded on the coverslips were fixed with 4% paraformaldehyde for 15 min and
then permeabilized with 0.1% Triton X-100 in PBS for 15 min. HDFa were washed twice with
PBS and blocked with 5% BSA solution at room temperature in humidity box for 30 min. HDFa
were incubated with primary α-SMA antibody with 1:500 dilutions in 5% BSA solution at 4 ˚C
overnight. HDFa were washed with PBST three times each time 5 min and then incubated with
secondary antibody conjugated with fluorescence dye at room temperature for 30 min. If another
fluorescence dye was needed, the slides were incubated with another primary antibody at room
temperature for 2 hours and secondary antibody conjugated with fluorescence dye for 30 min.
The slides were washed and mounted with Prolong Gold Antifade Mountant with DAPI. The
coverslips were sealed by nail polish. The results of immunofluorescence staining were acquired
by using Zeiss LSM 700 Confocal.
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3.5.3 Cell Attachment Assay
HDFa were cultured in good condition. rPKM1, rPKM2 or BSA was coated on the 24well plate at 4 ˚C overnight. The wells were washed with PBS twice and then blocked with 5%
BSA at room temperature for 1 hour. HDFa were trypsinized and pre-treated with LM609 or
BSA as control. HDFa were seeded on the plate and incubated for 2 to 4 hours. After wash twice
with PBS, the unattached cells were washed and the attached cells were stained with crystal
violet. The cell number in each well was counted for comparison of the cell attachment.
3.5.4 Crosslink
HDFa were harvested and washed with PBS. The membrane proteins were extracted by
using a membrane protein extraction kit. The membrane protein lysates were incubated with
rPKM2 at room temperature for 2 hours. Glutaraldehyde (1:100) was added in the reaction and
incubated for another 30 min. 1 M Tris/glycine was added into to the reaction to reach a final
concentration of 100 mM to stop the crosslink reaction. The magnetic Ni2+ beads were added in
to the lysate and incubated at room temperature for 1 hour. The beads were washed 3 times with
PBS, and then eluted by imidazole. The elution was dialyzed in ammonium bicarbonate at 4 ˚C
twice each time 4 hours. The sample was concentrated using lyophillizer and trypsinized using
the kit from Sigma. The sample was desalted using C18 tip. The final samples were sent to mass
spectrophotometer for analysis.
3.5.5 Immunoprecipitation
HDFa membrane proteins were extracted using the membrane protein extraction kit. The
membrane protein lysates were incubated with rPKM2 at room temperature for 2 hours and the
PKM2 antibody was added into the lysate and incubated at 4 ˚C overnight. The protein G
Agarose beads were added into the lysate and incubated at 4 ˚C for 2 hours. The beads were
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collected by centrifugation at 13000 rpm and washed three times with PBS. The beads were
resuspended in the sample loading buffer and boiled for 5 min. The samples were loaded for
SDS-PAGE and later for western blot analysis.
3.5.6 PI3K Activity Assay
The PI3K activity was measured by ADP-GloTM Lipid Kinase Systems from Promega
followed the instruction. Generally, the cells were inducted first with TGF-β or rPKM2 for two
days and cell lysates were made using RIPA buffer. The lysates were pulled-down by Pi3K
antibody and incubated with ATP and lipid substrate. The PI3K activity was measured by
monitoring the increase of ADP level.
3.5.7 PAK2 Activity Assay
The PAK2 activity was measured by in vitro protein kinase reaction and then western
blot to test the phosphorylation. The cells were inducted first with TGF-β or rPKM2 for two days
and cell lysates were made using RIPA buffer. The lysates were pulled-down by PAK2 antibody.
The in vitro protein kinase reaction consisted with PAK2 antibody pulldown lysate, 25 mM Tris
pH 7.4, 10 mM MgCl2, 1 mM DTT, 5 µM ATP, and 5 µg of myelin basic protein. The reaction
was preceded at 37 ˚C for 30 min. The reaction was stopped by adding loading buffer and boiled
for 5 min. The samples were loaded for SDS-PAGE and phospho-myelin basic protein antibody
was used in the western blot.
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Figure 3.1 Identification of α-SMA in wound healing.
(A). IF staining of α-SMA in wound skin. Frozen section of wound skin were cut and stained
with α-SMA antibody in green. (B). Quantification of α-SMA staining. IF staining of α-SMA
were quantified with ImageJ for the area of positive pixel. (C). Quantification of α-SMA staining
in PKM2 antibody treated group. IF staining of α-SMA were quantified with ImageJ for the area
of positive pixel. (D). Quantification of α-SMA in time series wound. Wound skin was collected
at day 3, day 6 and day 8. Staining of α-SMA was quantified with ImageJ for the area of positive
pixel.
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Figure 3.1 Identification of α-SMA in wound healing.
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Figure 3.2 Verification of myofibroblast and in vitro analysis of PKM2 effect on HDFa.
(A). Verification of myofibroblast. Myofibroblast was verified with myosin and ER-TR7
staining. (B). In vitro analysis of PKM2 effect on HDFa. Cell proliferation assay was analyzed
with BrdU proliferation assay. Cell migration assay was analyzed with boydem chamber assay.
Both assays were tested in buffer, rPKM1, and rPKM2 groups.
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Figure 3.2 Verification of myofibroblast and in vitro analysis of PKM2 effect on HDFa.
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Figure 3.3 Effect of PKM2 on HDFa.
(A). In vitro analysis of PKM2 in HDFa differentiation. HDFa differentiation was induced with
rPKM2 or TGFβ as positive control. Combination of rPKM2 and TGFβ was also applied.
Western blot was performed to test α-SMA level. (B). IF staining of differentiated HDFa cells.
rPKM2 and TGFβ were applied on HDFa cells. α-SMA was stained in green and phalloidin as
actin indicator was stained in red. (C). Collagen level in culture media. Collagen level was test
using antibody in Western blot.
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Figure 3.3 Effect of PKM2 on HDFa.
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Figure 3.4 Extracellular PKM2 activates integrin αvβ3 signaling.
(A). Cell attachment assay of HDFa cells. rPKM2 and rPKM1 were coated on plate and HDFa
cells were added in with αvβ3 antibody or BSA. (B). Immunoprecipitation of rPKM2 with HDFa
membrane protein lysate. PKM2 antibody and IgG were used for IP. β3 antibody was used to test
αvβ3 in the IP result. (C). The highlighted peptide fragments from trypsin digestion of rPKM2HDFa crosslinks and MALDI-tof/tof analyses that match the amino acid sequence of integrin
αvβ3. (D). rPKM2 enhanced migration ability of HDFa was inhibited by αvβ3 antibody.
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Figure 3.4 Extracellular PKM2 activates integrin αvβ3 signaling.
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Figure 3.5 Extracellular PKM2 activates HDFa through integrin αvβ3.
(A). Signaling pathway of extracellular PKM2 activating HDFa differentiation is independent of
TGFβ pathway. TGFβ receptor inhibitor and TGFβ antibody were used to test the effect of
rPKM2. P-Smad2 was used to represent as the classical signaling pathway of TGFβ. (B). αvβ3
antibody eliminates the effect of rPKM2 on activation of α-SMA expression in HDFa. (C). FAK
inhibitor reduces the effect of rPKM2 on activation of α-SMA expression in HDFa.
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Figure 3.5 Extracellular PKM2 activates HDFa through αvβ3.
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Figure 3.6 Extracellular PKM2 activates HDFa differentiation via PI3K.
(A). PI3K activity is upregulated in the rPKM2 treated HDFa. TGFβ receptor inhibitor and FAK
inhibitor was used as controls. (B). Phosphorylation of PAK2 was used as an indicator to test the
downstream pathway of extracellular PKM2 activating α-SMA expression. (C). Inhibitor
screening of extracellular PKM2 effect. PI3K inhibitor, Src inhibitor, and MEK inhibitor were
tested.
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Figure 3.6 Extracellular PKM2 activates HDFa differentiation via PI3K.
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CHAPTER 4 EXTRCELLULAR PKM2 PLAYS A ROLE IN LIVER FIBROSIS
4.1

Abstract
Liver fibrosis is caused by chronic inflammation and activation of Hepatic Stellate Cells

(HSCs). The resistance of HSCs to apoptosis is the main reason for non-reversal of liver fibrosis.
However, the molecular mechanism of how activated HSCs are prevented from apoptosis is still
not well understood. Here, we report that extracellular PKM2 exists in the liver tissue of liver
fibrosis patients. Extracellular PKM2 promotes progression of liver fibrosis by protecting
activated HSCs from apoptosis. PKM2 interacts with integrin αvβ3 on the cell surface of HSCs
and activates FAK-PI3K pathway to stimulate survival signal. Neutralization of extracellular
PKM2 by a specific antibody relieves the process of liver fibrosis. Our study uncovers a novel
mechanism of activated HSCs survival during liver fibrosis. The positive effect of PKM2
antibody treatment also suggests a possible therapeutic method for liver fibrosis.
4.2

Introduction
Liver fibrosis is the result of chronic liver damage which causes persistent inflammation

at injury site. Inflammatory response continuously activates HSCs to differentiate into
myofibroblast. Activated HSCs secret large amounts of extracellular matrix proteins that disrupt
the architecture of liver tissue and restrains the normal liver function (Friedman, 2003). Liver
fibrosis is considered “irreversible” because apoptosis of activated HSCs is reduced under the
effect of chronic inflammation. However, a few studies have shown that low degree of liver
fibrosis was reversible in certain circumstances. The study focusing on the apoptosis of activated
HSCs is still the major target of liver fibrosis recover (Benyon & Iredale, 2000; Elsharkawy et al.,
2005).
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The serum and stool level of PKM2 is highly correlated with several immune diseases
with strong inflammatory response. In the previous study, we found that extracellular PKM2
releases from activated neutrophils and facilitates wound healing by activating angiogenesis and
granulation tissue formation. PKM2 activates myofibroblast differentiation through an integrin
αvβ3-PI3K signal pathway.
4.3

Results

4.3.1 Identification of PKM2 in liver diseases
To explore whether extracellular PKM2 plays a role in liver injury repair, we carried out
IHC analysis of human liver disease tissue array using PKM2 antibody. High level of
extracellular PKM2 was detected in viral hepatitis and liver cirrhosis (Figure 4.1 A). PKM2 level
was gradually increased as the degree of liver disease progression. It showed a small increase in
viral hepatitis samples, and had a significant increase in liver cirrhosis samples. As control, no
PKM2 was detected in normal hepatic tissue sample. We classified the degree of staining into
three categories, weak, medium, and strong. It showed that most of the normal hepatic tissue had
weak PKM2 level, and viral hepatitis shifted to the medium level. Liver cirrhosis had huge
increase in the strong category. (Figure 4.1 B). To confirm our tissue array analysis, we analyzed
several freshly collected tissue samples from patients of liver cirrhosis. In consistent with the
tissue array analysis, we observed strong extracellular PKM2 staining with tissue sample of liver
cirrhosis, compared with normal hepatic tissue and viral hepatitis. The classified categories
represented similar portion as in the tissue array (Fig. 4.1 C&D). ELISA assay of patient blood
sample showed that PKM2 was detected in the blood circulation of patients with viral hepatitis
and liver cirrhosis (Fig. 4.1 E). These results indicate that PKM2 is released to extracellular
space of liver cirrhosis patients.
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4.3.2 Extracellular PKM2 promotes liver fibrosis
To study the function of extracellular PKM2 during liver fibrosis, a TAA/alcohol induced
liver fibrosis mouse model was established. TAA/alcohol treatment is commonly used to induce
liver fibrosis in mouse and rat model. TAA (Thioacetamide) is an organic molecule with sulfate
group and is known as a potent centrilobular hepatotoxicant to induce liver injury with certain
dosage (LD50, 300 mg/kg in mouse and rat). After administration of TAA, it undergoes a twostep process from TAA to thioacetamide sulphoxide (TASO), and then thioacetamide-S, Sdioxide (TASO2), which is an active metabolite. This process releases inducible nitric oxide
synthase (iNOS) and nuclear factor-κB that causes apoptosis and necrosis (T. M. Chen et al.,
2008). Liver undergoes inflammation after injury caused by TAA. Long time treatment of TAA
induces chronic inflammation and continuously activates HSCs to develop liver fibrosis.
In our experiment, TAA was treated for two and a half weeks, and then buffer, rPKM1,
and rPKM2 were added into the treatment respectively for three and a half weeks (Figure 4.2 A).
Mouse body weight was measured though out the whole experiment. Starting from the injection
of TAA at day 1, the average body weight of control group elevated compared with that of in the
groups of TAA treatment. After rPKM2 was combined into the TAA injection, the body weight
of TAA+rPKM2 group began to decrease and showed a significant difference at day 26. Body
weights of TAA+rPKM2 group went to a steady level at day 34, and maintained a 2 grams
difference compared with TAA+rPKM1 and TAA+buffer groups. Since the mice in control
group kept growing, the final body weight difference between TAA and non-TAA groups was 5
grams (Figure 4.2 B). After 6 weeks, livers were dissected and liver weight was measured. TAA
treatment significantly increased liver weight, and the addition of rPKM2 had even more
enhancement (Figure 4.2 C). Liver pictures were taken after six weeks of the treatment. TAA
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treatment resulted in the increase of liver size. Some livers in TAA+rPKM2 groups had obvious
bigger size compared with the livers in other groups (Figure 4.3 A) Close look of the liver
surface showed typical fibrotic features on the liver of TAA treated groups. The liver from
TAA+rPKM2 group had more white and yellow dots on the surface, considered as the typical
liver fibrotic signs (Figure 4.3 B)
4.3.3 Combination of rPKM2 and TAA causes more damage to liver function and
architecture
To study the liver function in different groups, serum markers (albumin, ALT, and AST)
reflecting liver function were screened. In albumin test, TAA treatment significantly increased
the serum level of albumin, but there was no difference between TAA+buffer, TAA+rPKM1,
and TAA+rPKM2. In ALT and AST tests, TAA treatment had three-fold increase compared with
control, and TAA+rPKM2 treatment doubled the effect of TAA treatment (Figure 4.4 A). To
observe the architecture of liver tissue, we used Sirius Red to stain collagen in liver tissue.
Control group did not have much collagen signal. Only a little was stained around blood vessels.
TAA+buffer and TAA+rPKM1 groups showed increased collagen staining, that thin collagen
bridges were formed between portal tracts. TAA+rPKM2 groups had extensive level of collagen
with thick band and collagen bridges crossing portal tracts. (Figure 4.4 B) Quantification of
collagen staining using FRIDA software revealed that TAA treatment induced the expression of
collagen, and addition of rPKM2 resulted in dense collagen pattern and disrupted tissue structure
(Figure 4.4 C). Other serum markers reflecting liver function were screened. All TAA treatments
elevated the levels of cholesterol and total protein compared with control group.
Only TAA+rPKM2 group had increased total bilirubin level (Figure 4.5 A). Liver
fibrosis induces apoptosis of hepatocytes and generates apoptotic bodies in the liver tissue. The
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number of apoptotic bodies is another way to analyze liver fibrosis. We stained the liver sections
by H&E staining. The apoptotic bodies were marked with arrows. Control group did not have
any apoptotic body, whereas TAA treatment damaged liver and showed typical apoptotic bodies
in the liver sections. In addition, TAA+rPKM2 revealed more apoptotic bodies, indicating more
damage to the liver tissue (Figure 4.5 B&C).
To test whether extracellular PKM2 can induce liver fibrosis, rPKM2 treatment without
injection of TAA was compared with TAA treatment and control. We performed the same
procedure as in the previous model. rPKM2 only group did not have any change in body weight
and liver weight compared to control group (Figure 4.6 A&B). The liver size in rPKM2 only
group showed similar as in control group (Figure 4.6 C). Both rPKM2 only group and control
group had no significant collagen staining compared with TAA+buffer group (Figure 4.6 D)
4.3.4 Extracellular PKM2 protects activated HSCs from apoptosis
Addition of rPKM2 to TAA treatment induced more activated HSCs in liver tissue, which
was marked by α-SMA in red. Apoptotic cells around HSCs were stained in green with TUNEL.
The number of apoptotic cells was decreased in the TAA+rPKM2 treatment (Figure 4.7 A&B).
Given that HSCs apoptosis is involved in liver fibrosis, we questioned whether extracellular
PKM2 can affect HSCs apoptosis to promote liver fibrosis. We first tested the effect of
extracellular PKM2 in HSCs in vitro using MTT assay. Primary HSCs were purchased and
cultured for at least 7 days to obtain α-SMA activation (Figure 4.7 C). FasL and TRAIL were
applied to induce apoptosis which reduce the absorbance in MTT assay, but addition of rPKM2
brought it back (Figure 4.7 D). Similar experiment was done using LX-2 cells also showed that
rPKM2 treatment reduced the apoptotic level of LX-2 after TRAIL induction (Figure 4.7 E).
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4.3.5 PKM2 interacts with integrin αvβ3 on the cell surface of HSCs
Our laboratory found that extracellular PKM2 interacted with integrin αvβ3 on the cell
surface of endothelial cells and HDFa cells. Activated HSCs has been shown to have enhanced
integrin αvβ3 expression. We performed the same crosslinking experiment and mass
spectrometry assay to detect what is the cell surface target of PKM2 on HSCs. Several protein
bands were found in the crosslinked result (Figure 4.8 A). Integrin αvβ3 was identified (Figure
4.8 B&C). We confirmed this interaction with PKM2 antibody pull-down assay and cell
attachment assay with rPKM2 coated on the plate (Figure 4.8 D&E)
4.3.6 PKM2 activates the survival signal of activated HSCs through integrin αvβ3, PI3K,
and NFκB
To pursue the interaction between PKM2 and integrin αvβ3, we added integrin αvβ3
antibody to the MTT assay and found it disrupted the protecting effect of rPKM2 (Figure 4.9 A).
Since FAK is the downstream pathway of integrin αvβ3, we then tested the effect of FAK
inhibitor in the rPKM2 protection of LX-2 cell apoptosis. As expected, rPKM2 induced the
viability of LX-2 cells back to normal level, but addition of FAK inhibitor eliminated its benefit
(Figure 4.9 B). In the extracellular PKM2 activated HDFa case, we discovered that PI3K is
activated. Since PI3K is an important factor in the survival signaling pathway, we revealed that
PI3K was activated in LX-2 cells after treatment of rPKM2 and the activity was reduced when
FAK inhibitor was added (Figure 4.9 C). Further apoptotic test found that PI3K inhibitor also
disrupted the protection of rPKM2 for the TRAIL induced LX-2 cell apoptosis (Figure 4.9 D).
NFκB is known as a downstream factor of PI3K mediated survival signaling pathway. We then
examined whether NFκB play a role in the activation of PI3K by extracellular PKM2 in HSCs.
NFκB activity was measured by NFκB transcription factor assay. rPKM2 treatment significantly
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elevated the activity of NFκB compared with control. This activation was inhibited by both αvβ3
antibody and PI3K inhibitor (Figure 4.9 E).
4.3.7 Neutralization of extracellular PKM2 facilitates liver recovery from TAA/alcohol
induced fibrotic damage
Since PKM2 is found extracellularly during liver fibrosis, we wondered whether
neutralization of extracellular PKM2 can relieve the liver tissue damage. To find the appropriate
PKM2 antibody for animal experiment, we tested the blocking ability of PKM2 antibody in LX2 cell attachment assay. We first picked two antibodies recognizing only PKM2 but not PKM1
(Figure 4.10 A). We tested this pair of PKM2 antibody IgGPK16 and IgGPK21. IgGPK16 had
very good effect of blocking the attachment of LX-2 cell on rPKM2 coated plate (Figure 4.10 B).
This set of mouse liver fibrosis model was designed by treating TAA/alcohol for 12 weeks and
then following 10 doses of PKM2 antibody and control antibodies (buffer, IgGCon, and
IgGPK21) (Figure 4.10 C). Mouse body weights were measured through the experiment. During
the 12-weeks of TAA/alcohol treatment, body weight of TAA treated groups was significantly
lower compared with control group. After stop of TAA/alcohol treatment, body weight of
IgGPK16 group had faster increase than other control groups (Figure 4.10 D). Final liver weights
showed that buffer, IgGCon, and IgGPK21 group had about 0.5 g increase compared with
control, and body weight of IgGPK16 group reduced close to control level (Figure 4.10 E).
Liver pictures clearly showed the liver size of buffer, IgGPK21, and IgGCon groups were
bigger than IgGPK16 group (Figure 4.11 A). Close examination of liver surface revealed bigger
size and typical fibrotic feature in buffer group. IgGPK16 group had similar liver size and
surface features compared to control group (Figure 4.11 B). To test the effect of PKM2 antibody
in liver function and architecture, we did both serum marker screen and Sirius Red staining to
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stain collagen. In the serum albumin level, all treatments had increased compared with control,
and there was no difference among them. In the serum ALT and AST levels, all treatments also
increased compared with control, but IgGPK16 treatment reduced ALT and AST levels after the
whole experiment (Figure 4.12 A). In the Sirius Red staining result, buffer, IgGCon, and
IgGPK21 groups presented dense collagen with network structure. On the other hand, IgGPK16
group indicated reduction of collagen expression (Figure 4.12 B&C). In the H&E staining result,
IgGPK16 treatment showed less numbers of apoptotic bodies indicating the relief of liver
fibrosis (Figure 4.13 A). Double staining of α-SMA and TUNEL showed that IgGPK16
treatment had less α-SMA expression but more apoptotic cells compared with IgGCon treatment
(Figure 4.13 C).
Previously, we reported that PKM2 can be released from infiltrated neutrophils during
wound repair process. The released PKM2 promotes wound repair. Very similar to the case of
cutaneous wound, liver injury would also trigger strong immune responses with neutrophil
infiltration/activation. Thus, it is expected that high levels of infiltration neutrophils would be
presented in fibrotic liver. Indeed, IHC staining of liver tissue array showed that neutrophils
presented at high levels in liver cirrhosis tissue samples (Figure 4.14 A). The observation clearly
supported the notion that activated neutrophils release PKM2. Extracellular PKM2 acts on
integrin αvβ3 of HSCs to promote activated HSCs survival. A number of previous studies
showed that activation of several pairs of integrin facilitates fibrosis progression, including αvβ6,
αvβ8, and αvβ1. It is believed that the effects of these integrin pairs on fibrosis progression are
mediated via activation of latent TGFβ. Thus, we asked whether extracellular PKM2 acted by a
similar mechanism in facilitating liver fibrosis progression. We tested the effects
neutralize antibody and a TGFβ receptor inhibitor on the activity of extracellular PKM2. Clearly,
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the function of extracellular PKM2 was TGFβ signaling independent (Figure 4.14 B).
Furthermore, TGFβ receptor was not activated in LX-2 cells upon rPKM2 treatment (Figure 4.14
C). Cell attachment assays demonstrated that integrin αvβ6 and αvβ1 expressing CHO cells did
not attach to rPKM2 coated plates (Figure 4.14 D), indicating that PKM2 did not interact with
these integrins.
4.4

Discussion
We demonstrated that extracellular PKM2 promotes liver fibrosis by protecting activated

HSCs from apoptosis. Our laboratory previously discovered that neutrophils releases PKM2
activated myofibroblast differentiation of dermal fibroblasts via integrin αvβ3 signaling pathway.
By interacting with the same target on cell surface, extracellular PKM2 stimulates different
reactions in dermal fibroblasts and HSCs. We questioned what could be the reason of this
alternative function. Is extracellular PKM2 also involved in the transformation from HSCs to
myofibroblasts? Integrin αvβ3 signaling is involved in several pathways. Multiple factors can
activate integrin αvβ3 in addition to its natural ligand vitronectin. We cannot exclude the
function of PKM2 activating differentiation in HSCs during liver fibrosis. More tests related with
myofibroblast differentiation of HSCs should be done in the future.
PKM2 antibody treatment showed promising effect in the TAA/alcohol induced mouse
fibrosis model. We questioned can PKM2 antibody treatment fully reverse liver fibrosis? In our
experiment, after 12 weeks of TAA/alcohol treatment, PKM2 antibody was applied for 20 days.
Body weight of IgGPK16 group was still about 2 grams smaller than control group. Extension of
PKM2 antibody treatment might provide better result that IgGPK16 group can catch up control
group. Collagen staining result showed that the IgGPK16 group still maintains certain amounts
of collagen. The digestion of remaining collagen by MMPs would take longer time. In this
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TAA/alcohol induced mouse liver fibrosis model, the stage of fibrosis was still considered in
early or middle stage corresponding to the collagen staining pattern. At this stage, liver fibrosis
could be still reversible, because of the high metabolism of mouse. Different mouse fibrosis
models, such as CCl4, dimethylnitrosamine (DMN), bile duct ligation, and concanavalin A
should be tested with PKM2 antibody treatment to confirm the effect of reversing fibrosis.
4.5

Materials and Methods

4.5.1 Liver fibrosis induction and treatments
All animal experiments were carried out in accordance with the guidelines of IACUC of
Georgia State University. Balb/c mice (6-7 week old male) were I.P. injected with 100 mg/kg
TAA and gradually increased to 200 mg/kg TAA in two weeks. 10% alcohol was also fed to
mice along with the TAA treatment. For rPKM2 experiment, 5 mg/kg of rPKM2 was mixed with
TAA for injection starting at two and a half week, and lasted for total of seven weeks. TAA
mixed with buffer or rPKM1 was the control. For the PKM2 antibody experiment, TAA was
continuously treated for twelve weeks. After that, TAA and alcohol was stopped and 4mg/kg of
PKM2 antibody was I.P. injected every other day for ten doses. Buffer and rabbit IgG was the
control. The body weights were recorded every week or every four days. At the end of the
experiments, animals were sacrificed. Livers, other organs, and blood samples were collected.
Liver weights were measured and liver pictures were taken. Tissue sections were prepared and
analyzed by IF, IHC, or H&E stains using commercially available antibodies as indicated. Serum
samples were prepared from collected blood samples. The serum samples were analyzed by the
service of Comparative Clinical Pathology.
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4.5.2 Sirius Red staining and analysis for collagen
Sirius Red staining was used the NovaUltraTM Sirius Red Stain Kit from IHCWORLD.
The staining procedure was basically followed the protocol provided in the kit. In brief, the
paraffin embedded slides were deparaffinized in xylene, 100% alcohol, 95% alcohol, 70%
alcohol, 50% alcohol, 30% alcohol, and then distilled water. The slides were stained in Weigert’s
Hematoxylin Solution for 10 min, and washed with running tap water for 10 min. Then, the
slides were incubated in Pico-Sirius Red Solution for one hour and followed with Acetic Acid
Solution for 1 min. The cells were stained in light brown and collagen was stained in red. The
slides were dehydrated through increased concentration of alcohol and mounted in a resinous
mounting medium. The pictures of collagen staining were taken with microscope under X100
magnification. The density of collagen staining was quantified using FRIDA software.
4.5.3 MTT assay
MTT assay was used to measured HSCs and LX-2 cell viability. MTT was dissolved at 5
mg/ml in specific culture medium to make the stock solution. The solution was filtered through a
0.22 μm filter before adding into the culturing cells. MTT stock solution was added to each well
at a 1:10 dilution and incubated for 3 to 4 hours. At the end of the incubation period, the culture
media were removed and acidic isopropanol was added into each well to solubilize the dye.
Absorbance of solubilized dye was measured at a wavelength of 570 nm with background
subtraction at 690 nm.
4.5.4 NFκB transcription factor assay
Activity of NFκB was measured by an NFκB p50/p65 EZ-TFA transcription factor assay
kit. The flanked DNA binding consensus sequence for NFκB was coated on the plate. After
incubation with cell extracts, activated NFκB was captured by the plate. The bound NFκB
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transcription factor unit p50 and p65 were detected by specific antibodies similarly as in ELISA
procedure.
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Figure 4.1 Identification of PKM2 in liver diseases.
(A) Immunohistochemistry staining of PKM2 in liver cirrhosis or hepatitis tissue microarray.
Microarray is stained with PKM2 antibody. Samples are separated to three groups, normal
hepatic tissue, viral hepatitis, and liver cirrhosis. (B) Quantification of PKM2 staining in
microarray. PKM2 intensity is divided into three categories: weak (<2000), medium (2000-5000),
and strong (>5000). Each core is examined and classified into one of the previous three
categories. (C) IHC staining of PKM2 in hepatitis and cirrhosis patient liver samples. (D)
Quantification of PKM2 staining fresh patient samples. PKM2 intensity is divided into three
categories: weak (<2000), medium (2000-5000), and strong (>5000). Each section is examined
and classified into one of the previous three categories. (E) Serum PKM2 levels of viral hepatitis
and liver cirrhosis patients.
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Figure 4.1 Identification of PKM2 in liver diseases.
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Figure 4.2 Addition of PKM2 affects body weight and liver weight in the TAA/alcohol
mouse model.
(A) Liver fibrosis mouse model diagram. (B) Average mouse body weight through the treatment
(6 weeks). (C) Average mouse liver weight at the end of the experiment.
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Figure 4.2 Addition of PKM2 affects body weight and liver weight in the TAA/alcohol
mouse model.
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Figure 4.3 Addition of PKM2 promotes liver fibrosis in the TAA/alcohol mouse model.
(A) Liver pictures of different groups. (B) Liver zoomed-in pictures of control, TAA+buffer,
and TAA+rPKM2 groups.
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Figure 4.3 Addition of PKM2 promotes liver fibrosis in the TAA/alcohol mouse model.
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Figure 4.4 Addition of PKM2 deals more liver damage in the TAA/alcohol mouse model.
(A). Serum marker analysis in different groups. (Albumin, ALT, and AST) (B). Sirius Red
staining of paraffin embedded liver samples. Light brown color indicates background cell
staining, and red color indicates collagen staining. (C) Quantification of Sirius Red staining for
collagen.
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Figure 4.4 Addition of PKM2 deals more liver damage in the TAA/alcohol mouse
model.
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Figure 4.5 Addition of PKM2 induces apoptotic body number in the TAA/alcohol mouse
model.
(A). Serum markers analysis in different groups (cholesterol, total protein, and total bilirubin).
(B). H&E staining of paraffin embedded liver samples. Nucleus is stained in purple, and cytosol
is stained in pink. Apoptotic bodies are marked with arrows. (C) Quantification of apoptotic
bodies.
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Figure 4.5 Addition of PKM2 induces apoptotic body number in the TAA/alcohol
mouse model.
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Figure 4.6 Treatment of PKM2 only does not induce liver fibrosis.
(A) Mouse body weights through the treatment (rPKM2 only). (B) Mouse liver weights at the
end of the experiment (rPKM2 only). (C) Liver pictures of different groups (rPKM2 only). (F)
Sirius Red staining of paraffin embedded liver samples (rPKM2 only).
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Figure 4.6 Treatment of PKM2 only does not induce liver fibrosis.
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Figure 4.7 Extracellular PKM2 protects activated HSCs from apoptosis.
(A) Immunofluorescence staining of frozen liver samples. Green color indicates TUNEL, and red
color indicates α-SMA. (B) Quantification of α-SMA intensity vs numbers of TUNEL nucleus.
(C) Immunoblot of α-SMA in HSCs before and after activation. (D) rPKM2 treatment protects
HSCs from FasL and TRAIL induced apoptosis. (E) rPKM2 treatment protects LX-2 cells from
TRAIL induced apoptosis.
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Figure 4.7 Extracellular PKM2 protects activated HSCs from apoptosis.
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Figure 4.8 PKM2 interacts with integrin αvβ3 on the cell surface of LX-2 cells.
(A) SDS-PAGE of LX-2 cell membrane extract with or without crosslink. Arrows indicate
possible integrin proteins. (B) Mass spectrometry analysis of digested protein bands showed
integrin αv in the result. (C) Mass spectrometry analysis of digested protein bands showed
integrin β3 and PKM2 in the result. (D) Attachment assay of LX-2 cells on different coatings.
BSA or integrin αvβ3 antibody is pre-treated before the assay. (E) PKM2 antibody IP result of
membrane extract of LX-2 cells.
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Figure 4.8 PKM2 interacts with integrin αvβ3 on the cell surface of LX-2 cells.
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Figure 4.9 PKM2 activates the survival signal of activated HSCs through integrin αvβ3,
PI3K, and NFκB.
(A) rPKM2 treatment protects LX-2 cells from apoptosis, which is disrupted by αvβ3 antibody
in MTT assay. (B) FAK inhibitor diminishes the protection of PKM2 in LX-2 cell apoptosis in
MTT assay. (C) PI3K activity assay of LX-2 cells. (D) PI3K inhibitor reduces the protection of
PKM2 in LX-2 cell apoptosis in MTT assay. (E) NFκB activity assay. αvβ3 antibody and PI3K
inhibitor decreases the NFκB activity induced by rPKM2 treatment in LX-2 cells.
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Figure 4.9 PKM2 activates the survival signal of activated HSCs through integrin αvβ,
PI3K, and NFκB.
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Figure 4.10 Neutralization of extracellular PKM2 in the TAA/alcohol mouse model.
(A) Attachment assay of LX-2 cells on rPKM2 coated plate with antibody blocking treatment. (B)
Immunoblot of PKM2 antibody: IgGPK16 vs IgGPK21. (C) Diagram of liver fibrosis mouse
model with antibody treatment (15 weeks). (D) Mouse body weights through the treatment. (E)
Mouse liver weights at the end of experiment.
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Figure 4.10 Neutralization of extracellular PKM2 in the TAA/alcohol mouse model.
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Figure 4.11 Neutralization of extracellular PKM2 facilitates liver recovery from the
TAA/alcohol induced fibrotic damage.
(A) Liver pictures of different groups. (B) Liver zoomed-in pictures of control, buffer, and
IgGPK16 groups.
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Figure 4.11 Neutralization of extracellular PKM2 facilitates liver recovery from the
TAA/alcohol induced fibrotic damage.
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Figure 4.12 Neutralization of extracellular PKM2 recovers liver function from the
TAA/alcohol induced fibrotic damage.
(A) Serum markers reflecting liver function (albumin, ALT, and AST). (B) Sirius Red staining
of paraffin embedded liver samples. (C) Quantification of Sirius Red staining for collagen.
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Figure 4.12 Neutralization of extracellular PKM2 recovers liver function from the
TAA/alcohol induced fibrotic damage.
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Figure 4.13 Neutralization of extracellular PKM2 affects apoptotic bodies and HSCs
apoptosis in the TAA/alcohol mouse model.
(A) H&E staining of liver sections. (B) Immunofluorescence staining of frozen liver samples. (C)
Quantification of α-SMA intensity vs numbers of TUNEL nucleus.
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Figure 4.13 Neutralization of extracellular PKM2 affects apoptotic bodies and HSCs
apoptosis in the TAA/alcohol mouse model.
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Figure 4.14 PKM2 activated integrin αvβ3 signal is independent of TGFβ signal.
(A) Quantification of IHC staining of Ly6G in liver disease tissue microarray. (B) TGFβ
antibody and TGFβ receptor inhibitor does not affect the activity of PKM2. (C) TGFβ receptor is
not activated upon treatment of PKM2. (D) CHO cells expressing integrin αvβ3 attach to the
rPKM2 coated plate, compared with integrin αvβ1 and αvβ6 expressions.
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Figure 4.14 PKM2 activated integrin αvβ3 signal is independent of TGFβ signal.
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Figure 4.15 Diagram of the whole process.
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Figure 4.15 Diagram of the whole process.
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CHAPTER 5 MATERIALS AND METHODS
5.1

Materials

5.1.1 Chemicals
Acetic Acid
Acrylamide
Agar
Agarose
Ammonium Persulfate (APS)
Ampicillin
ATP
Autoradiography film
Bacto Yeast Extract
Bacto Tryptone
Bis-Acrylamide (w/v 29:1)
β-Mercaptoethanol
Bromophenol Blue
Calcium Chloride
Cell culture media
Coomassie blue
Crystal Violet
Dithiothreitol (DTT)
Dimethyl Sulfoxide (DMSO)
ECL Western Blot substrate
Ethanol, 200 Proof
Ethidium Bromide
Ethylenediaminetetraacetic Acid (EDTA).
FAK inhibitor 14
Fetal Bovine Serum (FBS)
Formaldehyde
Formalin, 10% solution
Glycerol
Glycine
Hank's Balanced Salt Solution (HBSS)
HEPES
Hydrochloric acid
Imidazole
Isopropyl Alcohol
Isopropyl ß-D-1-thiogalactopyranoside(IPTG)

VWR international
VWR international
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Fisher Scientific
BD Biosciences
BD Biosciences
VWR International
Sigma Aldrich
EMD
Sigma Aldrich
Cellgro
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Thermo Scientific
VWR International
Sigma Aldrich
Sigma Aldrich
Millipore
Invitrogen Life Technologies
Sigma Aldrich
Sigma Aldrich
VWR International
VWR International
Invitrogen Life Technologies
Sigma Aldrich
VWR International
Sigma Aldrich
VWR International
Sigma Aldrich
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Kanamycin
Magnesium Chloride
Methanol
Nail Polish
Ni-NTA agarose
Penicillin-Streptomycin solution
Phenylmethylsulfonyl Fluoride (PMSF)
Ponceau solution
Potassium Chloride
Prolong gold anti-fade reagent with DAPI
Protein A agarose
Protein G agarose
Protein inhibitor cocktail
Phosphatase inhibitor cocktail I (Ser/Thr)
Phosphatase inhibitor cocktail II (Tyr)
RIPA buffer, 10X
Sodium Acetate
Sodium Chloride
Sodium Bicarbonate
Sodium Dodecyl Sulfate
Sodium Fluoride
Sodium Hydroxide
Sodium Pyruvate solution
N,N,N’,N’-TetramethylEthylenediamine
(TEMED)
Thiazolyl Blue Tetrazolium Bromide (MTT)
Tris base
Triton X-100
Trypan Blue solution
0.25% Trypsin-EDTA
Tween-20
Western Blot Stripping Buffer

Sigma Aldrich
Sigma Aldrich
VWR International
Fisher Scientific
Qiagen Inc.
Cellgro
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Invitrogen Life Technologies
Thermo Scientific
Millipore
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Millipore
Sigma Aldrich
VWR International
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Cellgro
Sigma Aldrich
Sigma Aldrich
Fisher Scientific
Sigma Aldrich
Sigma Aldrich
Cellgro
Sigma Aldrich
Thermo Scientific

5.1.2 Kits
Bio-Rad Protein Assay
Biocoat Cell Migration System
Nuclear Extraction Kit
QIAprep Spin Miniprep Kit
QIAquick Gel Extraction Kit

Bio-Rad Laboratories
BD Bioscience
Active Motif
Qiagen Inc.
Qiagen Inc.
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Wizard® plus DNA purification System

Promega

5.1.3 Laboratory Equipments
7500 Fast Real-Time PCR System
Allegra 6R Refrigerated Benchtop Centrifuge
C25 Incubated Floor Shaker
Class II Biosafety Cabinet
EC3 BioImaging System
Film Processor
French Presure Cell Press
Mastercycler Gradient
UV-1700 Spectrophotometer
Victor3 Multilable Plate Reader

Life Technologies
Beckman Coulter
New Brunswick Scientific
Labconco
UVP
Kodak
Aminco
Eppendorf
Shimadzu
Perkin Elmer

5.1.4 Enzymes and Recombinant Proteins
Alkaline phosphatase, Shrimp
C-Abl protein tyrosine kinase
DNase
MBD3
Pfu-DNA polymerase
Proteinase K
PDGF-AA
PDGF-BB
RNase A
Restriction enzymes
T4 Polynucleotide Kinase
T4-DNA ligase
YOP protein tyrosine phosphatase

Promega
New England BioLabs
Promega
BioClone
Promega
Sigma Aldrich
Pepro Tech
Pepro Tech
Thermo Scientific
Thermo Scientific
Promega
Thermo Scientific
New England BioLabs

5.1.5 Antibodies
β-Actin antibody (mouse monoclonal)
E-cadherin (mouse, monoclonal)
GAPDH antibody (mouse monoclonal)
HA antibody (mouse monoclonal)
HA antibody (rabbit polyclonal)

Santa Cruz Biotechnology
BD Biosciences
Thermo Scientific
Roche Applied Science
Lab generated
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6x-His antibody (rabbit polyclonal)
Histone 2A (rabbit polyclonal)

Abcam
Cell Signaling Technology

5.1.6 Bacteria strains and mammalian cell lines
BL21-CodonPlus (DE3)-RIL
JM109
Human Dermal Fibroblasts, adult (HDFA).
LX-2 Human Hepatic Stellate Cell Line
Primary Human Stellate Cells (HSC).

5.2

Stratagene
Promega
Thermo Fisher Scientific
Millipore
Zen-Bio, Inc.

Methods

5.2.1 Bacteria Culture
Different types of E. coli were cultured in LB (Lysogeny broth) medium with 1%
kanamycin at 37˚C and 250 RPM. JM109 was used for plasmid DNA duplication, BL21 (DE3)pLysS and Tuner were used for recombinant protein expression. For colony selection, agar plates
were made with LB medium-kanamycin and 15 g/L agar. For strain storage, the transformed
bacteria were mixed with sterile glycerol (30% (v/v)) and stored at -80˚C.
5.2.2 Transformation
To prepare the competent cells, single clone of bacteria strain was inoculated from the
plate to a 25 mL LB culture medium and shook at 37 ˚C overnight. The culture medium was then
centrifuged at 4 ˚C 5000 rpm for 20 min. The cell pellet was resuspended in sterile CaCl 2 and
centrifuged again. The cell pellet was resuspended in sterile water and aliquot to save in -80
aliquot.
For transformation, the competent cells were thawed on ice. The plasmids were add into
the cells and incubated on ice for 5 min. The mix was then transfer to 42 ˚C water bath to
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incubate for 90 seconds, and then on ice for 2 min. 500 μL of LB medium was added into the
mix and shaking incubate at 37 ˚C for 1 hour. After incubation, the mix was spread on the plates
using spatula.
5.2.3 Protein Purification
Cells were inoculated from one colony (or 10 µL stored cells) and shaking cultured in 5
mL LB with 0.1 % kanamycin at 37 °C overnight. Cells were transferred into 1 L LB medium
with 0.1 % kanamycin and shaking cultured for 3 to 5 hours at 37 °C to reach OD600 of 0.4.
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to reach 1 mM and incubated at 16 °C
overnight. Cells were harvested by centrifugation at 4 °C, 7000 rpm for 15 min. Cell pellets were
resuspended in buffer A (50mM Tris, pH 7.5, 0.1M KCl, 25mM MgCl2, 20% glycerol, 2 mM
DTT, and PMSF) and then lysed by french press. The lysates were centrifuged at 4 °C, 14000
rpm for 30 min. The supernatants were collected and filtered for protein purification. For protein
purification, PKM2 was fused with his-tag, therefore Ni2+ column was used to purify the protein
in FPLC. After purification, protein in tubes were collected and dialysis with buffer A overnight
at 4 °C. The purified protein was tested using SDS-PAGE.
5.2.4 Antibody Generation and Purification
The hybridoma with rabbit monoclonal PKM2 antibody production was generated by
Epitomics, Inc. Hybridoma was thawed in warm RPMI1640 medium with Epitomics' rabbit
hybridoma supplement A, 55 µM β-mercaptoehanol cell culture grade, and 10 % FBS in a 10 cm
petri-dish. The medium was changed every day until cells reached 80 % confluency. The cells
were trypsinized and cultured in T175 flask, then gradually moved to a 1 L cell culture bottle. To
stimulate the antibody production, culture medium was switch from RPMI1640 to serum-free
medium (Irvine scientific IS MAB-CD with 1% antibiotic/antimycotic, and 1% Glutamax). The
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cells were culture in serum-free medium for 7 to 10 days. To harvest the antibody, the cells
suspension was centrifuged at 4 °C, 3000 rpm for 15 min. The supernatant was collected for
antibody purification.
The rabbit monoclonal PKM2 antibody was purified using Protein G Agrose beads at 4
°C. The beads was packed into a column, and washed with ten column volumes of cold PBS.
The supernatant containing antibody was loaded in the column, and then washed with ten
volumes of cold PBS. The antibody was eluted with 50 mM glycine pH 2.7 into 1 mL fractions
containing the neutralization buffer (1M Tris, pH 8.0, 1.5 M NaCl, 1 mM EDTA).. Bradford
protein assay was used to measure the antibody concentration in each fraction. The high
concentration fractions were mixed, filtered, and aliquoted.
5.2.5 Cell Proliferation Assay
BrdU assay was used to measure cell proliferation. Cells were seeded into 96 well plate at
about 105 cells per well. Blank (no cells) and background (no BrdU label) controls were
established. BrdU label was diluted 1:2000, and 20 μL of it was added into each well. The cells
were incubated with BrdU label for 24 hours in the cell culture incubator. The wells were
emptied and refilled with 200 μL Fixative/Denaturing Solution, and then incubated at room
temperature for 30 min. The cells were incubated with diluted Anti-BrdU Antibody at room
temperature for 1 hour. After washing three times with Wash Buffer, the Peroxidase Goat AntiMouse IgG HRP Conjugate was diluted and added into each well to incubate at room
temperature for 30 min. The cells were washed again three times with Wash Buffer, and
incubated with Substrate Solution in the dark for 15 min followed with Stop Solution. The
readings were recorded at wavelength of 450 nm.
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5.2.6 Boyden Chamber Assay
The cells were cultured in good condition and prepared for the migration assay. 24-well
plate was used and fitted chambers were inserted into each well. 2 mL of culture medium with
10% FBS was added into each bottom well. The cells were resuspended into serum-free culture
medium. Each well was added with 2 x 104 cells. rPKM2 or other reagents were added into the
upper chamber as well. The plate was incubated in the incubator for 16 hours. After incubation,
the chambers were washed three times with PBS and stained with crystal violet for 3 min. The
wells were then washed and observed under microscope.
5.2.7 SDS-PAGE
The SDAS-PAGE gel was prepared before electrophoresis. The separating gel was first
set up at bottom with 6~12% acrylamide, 0.375M Tris-HCl pH 8.8, 0.1% SDS, 0.04% APS, and
0.08% TEMED). 1 mL of water was added on the separating gel to help it to polymerize firmly.
While waiting for polymerization of the separating gel, the stacking gel was prepared with 5%
acrylamide, 0.125M Tris-HCl pH 6.8, 0.1% SDS, 0.05% APS, and 0.15% TEMED. The stacking
gel was poured onto the separating gel and the comb was inserted to generate wells. The lysates
were diluted with 5X loading buffer (175 mM Tris-HCl pH 7.0, 5 mM EDTA, 10% SDS, 20%
sucrose, 0.01% bromophenol blue, and 28.8 mM β-mercaptoehanol) and boiled for 5 min. The
samples and protein ladder were loaded in the wells. The gel was ran at constant voltage 60 V
first at the stacking stage, and then increased to 80 V at the separating stage.
5.2.8 Western Blot
The protein samples were separated by SDS-PAGE. Proteins were transferred from gel to
a nitrocellulose membrane at constant current of 80 mA for 2 hours. The membrane was blocked
in 5% BSA solution (5% BSA in TBST (20mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-
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20)) at room temperature for 30 min. The membrane was washed with TBST three times, each
time 5 min. The primary antibody was diluted in the 5% BSA solution. The membrane was
incubated in it on a flat shaker at 4 ˚C overnight, and then washed three times again with TBST.
The membrane was incubated with appropriate secondary antibody against the primary with a
dilution of 1:2000 at room temperature for 30 min and followed with three times wash with
TBST. The signal was detected with chemiluminescence reagents and developed in dark room.
5.2.9 ELISA (enzyme-linked immuno assay)
ELISA was performed using ELISA 96-well plate. PKM2 antibody was first coated on
the plate at 4 ˚C overnight. Culture medium or serum were added into the plate and incubated at
room temperature for 2 hours. The plate was washed twice with PBST and then incubated with
detect antibody at 4 ˚C overnight. The plate was washed three times with PBST and followed
with secondary antibody treating at room temperature for 1 hour. TMB substrate solution was
added into the plate and incubated for 30 min. The reaction was terminated with adding stop
solution. The reading was recorded with spectrophotometer at wavelength 450 nm.
5.2.10 Preparation of Plasmid DNA
Purification of DNA plasmid from bacteria was using QIAprep Spin Miniprep Kit. 2 mL
of bacteria medium was inoculated with single colony from an agar plate, and then shaking
incubated at 37 ˚C overnight. The cell pellet was generated by centrifuging at 5000 rpm for 5
min and the supernatant was removed. The cell pellet was suspended in 250 µL of suspension
buffer supplemented with RNase A, and followed by adding 250 µL alkaline lysis buffer to lyse
the cells. After the lysate was adjusted to high-salt binding condition, the protein precipitation
was showed up and removed by centrifugation at 13000 rpm for 10 min. The supernatant

126

containing DNA was applied to the QIAprep column, and washed for several times. The plasmid
DNA was eluted by adding 50 µL of elution buffer and centrifugation.
5.2.11 Quantification of DNA Concentration
Concentration of DNA was determined by spectrophotometer at the wavelength of 260
nm. One unit of OD260 equated to 50 µg/mL of double-stranded DNA. The ratio of OD260 to
OD280 provided the purity of the DNA sample. If the ratio of OD260 to OD280 was higher than
1.8, the sample was considered as pure DNA.
5.2.12 Preparation of Whole Cell Lysates
After treatments, cells were washed three times with ice-cold PBS. RIPA buffer
supplemented with protease inhibitors cocktail was used to lyse the cells. The cells attached on
the plate were added with RIPA buffer and scraped off with a rubber scraper or pipette tip. The
lysates were transferred into a microtube and vortexed for 10 seconds. The lysates were then
rotated at 4 ˚C for 30 min, and centrifuged at 13000 rpm at 4 ˚C for 15 min. The supernatants
were stored at -20 ˚C freezer.
5.2.13 Quantification of Protein Concentration
The protein concentration in cell lysates and tissue homogeneous were measured by BioRad protein assay. A standard curve was generated using gradient concentrations of BSA
standard. To measure the protein concentration, 10 μL of lysates was mixed with 790 μL water
and 200 μL of Bio-Rad dye in a cuvette. The absorption readings were recorded with a
spectrophotometer at wavelength 595 nm. Each absorption reading was plotted into the BSA
standard curve to calculate the protein concentration.
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5.2.14 Immunofluorescence Staining
The frozen section slides were fixed in 95% ethanol and the extra gel was cleared. The
samples were circled with PAP pen and blocked with 5% BSA solution at room temperature in
humidity box for 30 min. The slides were incubated with primary antibody with 1:500 dilutions
in 5% BSA solution at 4 ˚C overnight. The slides were washed with PBST three times each time
5 min and then incubated with secondary antibody conjugated with fluorescence dye at room
temperature for 30 min. If another fluorescence dye was needed, the slides were incubated with
another primary antibody at room temperature for 2 hours and secondary antibody conjugated
with fluorescence dye for 30 min. The slides were washed and mounted with Prolong Gold
Antifade Mountant with DAPI. The coverslip was sealed by nail polish. The results of
immunofluorescence staining were acquired by using Zeiss LSM 700 Confocal.
5.2.15 Quantification of IF Staining
IF staining was quantified using ImageJ software. The fields were chosen randomly from
each group. Micro-vesicular density (MVD) and total positive area were quantified. MVD was
measured by counting the positive staining point in each field. Total positive area was measured
by selecting the positive staining pattern and calculating the area of each pattern.
5.2.16 Immunohistochemistry (IHC). Staining
IHC staining was performed following the protocol in Dr. Shi-Yong Sun’s lab in Emory.
Generally, the slides were baked at 60 ˚C for 2 hours, and then hydrated by continuously
incubating in the following solution in order (three times xylene, twice 100% ethanol, 90%
ethanol, 70% ethanol, 50% ethanol, 30% ethanol, and distilled water). The antigen retrieval was
done by incubating in 10 mM Sodium Citrate buffer pH 6.0 and microwaved for 5 min in high
and 10 min in low. After the slides were cooled down to room temperature for 39 min, they were
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washed with PBS for 5 min. The slides were incubated with Dual Endogenous Enzyme Block at
room temperature for 30 min and wash again. The slides were incubated with primary antibody
diluted in antibody diluents 1:500 at 4 ˚C overnight. The slides were washed with PBST twice
and PBS once. The slides were treated with Labeled polymer-HRP at room temperature for 30
min, followed by the same washes. Substrate chromogen solution was made by mixing 1 mL of
DAB+ substrate buffer plus 1 drop of DAB+ chromogen. The slides were added by DAB+
solution and monitored under microscope. The slides were counter stained with hematoxylin QS
for 1 min. The slides were dehydrated by reversely incubating from distilled water to xylene. The
slides were mounted and sealed with nail polish.
5.2.17 Quantification of IHC Staining
Quantification of IHC staining was done by using FRIDA (FRamework for Image
Dataset Analysis) software. All images ready to be analyzed were saved in the same folder. A
mask was selected by picking positive signals in different images. After the mask was well
defined, the software would calculate the area of expression pattern in other images. The results
from different groups were compared.ng the area.
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CHAPTER 6 CONCLUSIONS AND DISCUSSIONS
6.1

Extracellular PKM2 released from neutrophils facilitates wound healing by
promoting angiogenesis
Wound healing is a slow and complicated process that every step needs to organize well

for a proper recover. Since extracellular PKM2 promotes angiogenesis during tumor progression,
and angiogenesis is critical for the proliferation stage of wound healing, we study wound repair
with a mouse cutaneous wound model by topical application of rPKM2. Our results showed that
topical application of rPKM2 facilitates wound closure. Immune staining analysis using CD31
antibody found that topical application of PKM2 stimulates the growth of microvessel during
wound healing.
In mouse cutaneous wound model, the wound in rPKM2 treated group started to close
rapidly at day 3 compared with the wounds in control groups. However, the wound sizes in all
three groups were similar at day 8. What could be the reason of slower closure in the rPKM2
treated group after day 6? Since the wound pictures only showed the outside of mouse skin
recovery which is called re-epithelization, the outside appearance does not reflect the whole
process of wound repair. To examine what happen inside the wound site, we examined the
wound underneath of mouse skin. The rPKM2 treated group showed more established capillary
vessel structure and granulation tissues, compared with those in buffer and rPKM1 treated
groups. We thought that the topical application of rPKM2 facilitated the wound healing process
by promoting the angiogenesis in proliferation stage, which led to faster repair at day 3. Given
that the re-epithelization process is paralleled with angiogenesis and granulation tissue
formation, other factors slowed down the closure of wound in rPKM2 treated group to insure a
well-organized wound repair. It is also possible that the capillary structure in rPKM2 treated
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group might be excessive compared with those in normal wound repair. As it is known that the
process of wound healing needs to be regulated in an ordered manner. Angiogenesis and
formation of granulation tissue should be stopped at a certain time point. It was possible that
angiogenesis was extended due to addition of rPKM2 at day 6 in our experiment. To find a better
way of applying rPKM2 in the cutaneous wound healing, we should design a strategy to apply
rPKM2 at different time points to find the best fit for facilitating wound healing. This strategy
may lead to proper growth of granulation tissue.
In addition to the effect on angiogenesis, topical application of rPKM2 was also found to
promote growth of granulation tissue underneath the skin wound. Is the growth of granulation
tissue directly stimulated by extracellular PKM2 or by the PKM2 induced angiogenesis? At the
beginning, angiogenesis is very important for proliferation stage to support granulation tissue
growth. Thus, we believed that topical application of rPKM2 promoted angiogenesis, and the
newly grown capillary brought more nutrients to support the growth of granulation tissue.
However, we measured the thickness of granulation tissue and stained the fibroblast at the
wound site. The results suggested that rPKM2 might play a role on dermal fibroblasts during
cutaneous wound. I will discuss it in the second section of this chapter.
We discovered that endogenous PKM2 located in extracellular space at the wound site by
IHC staining of PKM2. Presence of PKM2 in the extracellular space of wound tissues suggested
a possible intrinsic mechanism of secretion of PKM2 during the wound repair process. Due to a
close correlation between neutrophils and PKM2 in a numbers of inflammatory diseases, we
performed a time course of staining of neutrophils and PKM2 during cutaneous wound healing.
Both neutrophils and PKM2 exhibited a similar timing of appearance peaked around day 3. It is
known that neutrophils express PKM2. Thus, we isolated neutrophils from mouse bone marrow
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and activated by fMLP. PKM2 was detected in the culture medium of activated neutrophils. The
release of PKM2 was inhibited by several degranulation inhibitors. To prove that extracellular
PKM2 is released from neutrophils in vivo during wound healing, we used beige mouse that
carries deficiency of neutrophil migration. Both neutrophils and PKM2 were not presented at the
wound site of beige mice. Neutrophils and PKM2 were found at wound site in the normal mice.
Therefore, we concluded that extracellular PKM2 was released from activated neutrophils during
wound healing.
In the future study, we would like to answer two questions. The first question is how
PKM2 is released from activated neutrophils. In cancer cells, reports suggested that PKM2 is
secreted from exosome. One proteomics study stated that PKM2 locates at the primary and
secondary granules. We found release of PKM2 correlated with the degranulation of neutrophil.
Degranulation activator fMLP and damnacanthal stimulated the release of PKM2. We thought
that PKM2 might interact with some granule proteins in the primary and secondary granules.
Screening of different degranulation inhibitors showed partial effects of all tested inhibitor
individually. To test which type of granule releases PKM2, we can co-stain PKM2 with the
cargo protein in granules to find the transportation pathway. Electron microscopy is another
method to study the transportation of PKM2. The second question is do other types of immune
cells release PKM2? PKM2 is reported to be expressed in platelets, neutrophils, macrophages,
and lymphocytes. (Hapa et al., 2011) As an example, it is possible that PKM2 is released from
macrophages to promote angiogenesis. We stained wound tissue sections with antibody against
one of macrophage markers F4/80 at day 2 of wound. No staining of macrophages was observed
compared with high level staining of Ly6G and PKM2. To see the correlation at late time points,
the samples from later stage of wound should to be stained with F4/80 and PKM2. Isolating
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monocytes and activating them is another way to test whether PKM2 is release from
macrophages in vitro.
If extracellular PKM2 released from neutrophils facilitates wound healing, then
neutralization by PKM2 antibody should affect the wound repair process. We designed another
experiment with mouse cutaneous wound model by injecting PKM2 antibody and followed by
the similar process in the previous experiment. The healing of wound was slowed down in the
PKM2 antibody treated group compared with buffer and IgG controls. The micro-vessels were
also limited in the PKM2 antibody treated group.
In brief, our study revealed an unexpected role of extracellular PKM2 in facilitating
wound healing by promoting angiogenesis. Release of PKM2 through degranulation of activated
neutrophils suggested a new and important link between immune response and proliferation
phase. This link provided an explanation of how neutrophil infiltration triggers early
angiogenesis during wound healing which indicated a physiological role of neutrophils in
addition to the anti-microbial function.
6.2

PKM2 promotes myofibroblast differentiation via integrin αvβ3
During the mouse wound healing experiment, we discovered that the granulation tissue of

PKM2 treated group was much thicker than those of control groups. We thought only by
promoting angiogenesis was not enough to stimulate the growth of granulation tissue.
Extracellular PKM2 released from activated neutrophils may play a role in fibroblast. Dermal
fibroblasts expressed high levels of integrin αvβ3. Myofibroblast differentiation is a key feature
during granulation tissue formation. Clearly, α-SMA, the myofibroblast marker, was upregulated
in the rPKM2 treated group during the wound healing.
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We questioned how extracellular PKM2 triggered the upregulation of α-SMA in
fibroblasts at the wound site. First, we tested the effect of extracellular PKM2 on HDFa cell
proliferation and migration. PKM2 did not exhibited any effect on HDFa proliferation, but
rPKM2 treated HDFa had significant increase in migration. Thus, we believed that extracellular
PKM2 at wound site activated migration of dermal fibroblasts and recruited more of fibroblasts
to the wound site. We subsequently tested the effect of extracellular PKM2 on HDFa
differentiation, and compared the effects of TGFβ, the well-known myofibroblast differentiation
activator. Surprisingly, rPKM2 independently induced the expression of α-SMA in fibroblasts.
PKM2 is as effective as TGFβ in inducing α-SMA expression in fibroblasts. Combination of
rPKM2 and TGFβ had an enhanced effect on α-SMA expression. Both rPKM2 and TGFβ treated
HDFa demonstrated a typical feature of differentiated myofibroblast with stress fiber bundles
and collagen secretion. To further test whether the activation of fibroblast by rPKM2 is
independent of TGFβ, TGFβ antibody was added to neutralize residue TGFβ and TGFβ receptor
inhibitor was also employed to inhibit the downstream signal pathway. The effect of TGFβ in the
presence of antibody and inhibitor was reduced, whereas the effect of rPKM2 was not affected.
Therefore, we concluded that extracellular PKM2 independently stimulates HDFa cell migration
and differentiation.
Several questions were raised regarding the promotion of HDFa differentiation by
extracellular PKM2. Is PKM2 itself enough to activate full differentiation of myofibroblast?
Mechanical force and other factors can partially activate myofibroblast differentiation. TGFβ is
required for fully activation of myofibroblast differentiation. α-SMA expression, collagen
secretion, fibers bundle, and cell contractile ability are used to analyze the degree of
differentiation. In our study, rPKM2 independently induced expression of α-SMA and secretion
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of collagen. However, rPKM2 induced less α-SMA expression and collagen secretion compared
with that of TGFβ treatment. In a confocal microscopic study of co-stain α-SMA with actin, both
rPKM2 and TGFβ treatments had increased spreading morphological change, increased α-SMA
expression, and α-SMA/actin bundles (yellow). To study the contractile ability of HDFa, we can
use collagen gel contraction assay that functionally tests the degree of myofibroblast
differentiation.
Our laboratory previously found that extracellular PKM2 interacted with integrin αvβ3
and activated integrin signaling in endothelial cells. Since HDFa also have integrin αvβ3
expression, it is highly possible that integrin αvβ3 is the target of extracellular on HDFa. We
performed chemical crosslinking followed by mass spectrometry analysis. We found that integrin
αvβ3 interacted with PKM2. Immunoblot of PKM2 pull-down further confirmed that integrin
αvβ3 was the target of extracellular PKM2. Attachment assay with plate coated with rPKM2
showed the interaction between PKM2 and integrin αvβ3 was blocked by LM609, an integrin
αvβ3 antibody. To test the downstream signaling pathway of PKM2-αvβ3 in myofibroblast
differentiation, we used several different inhibitors that inhibit the downstream protein kinases of
FAK. PI3K was found to be the major target. Furthermore, rPKM2 induced the activity of PI3K
in HDFa. Additional tests following PI3K demonstrated that PAK2 was the downstream pathway
in stimulating α-SMA expression.
Is integrin αvβ3 the only target of extracellular PKM2 in HDFa? One group reported that
PKM2 interacts with tumor endothelial factor 8 (TEM-8) on tumor endothelial cells. Our
laboratory observed that PKM2 interacted with integrin αvβ3 on endothelial cells. PKM2
interacted with TEM-8 weakly. In the mass spectrometry analysis of PKM2 interacting partners,
we identified several other proteins, including G3P, Hexokinase-1, ATP synthase, multiple
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coagulation factor deficiency protein 2, myosin regulatory light chain 12B, filamin-A, α-actinin,
tubulin, and HNRNP, could be PKM2 interacting proteins. These proteins can be separated into
several groups, such as glycolytic enzymes, skeleton proteins, and cell transportation proteins.
Apparently, none of these identified proteins located on the cell membrane. In our test, integrin
αvβ3 was the only cell surface receptor identified in mass spectrometry. If other membrane
targets exist, more detailed and specific mass spectrometry method should be applied in the
future.
TGFβ activates myofibroblast differentiation through TGFβ receptor and Smad family
pathway. Activation of fibroblast differentiation by PKM2-integrin αvβ3 interaction was
independent of TGFβ pathway. Do these two signal pathways crosstalk? TGFβ up-regulated the
expression of integrin αvβ3 in fibroblasts, endothelial cells, and cancer cells. TGFβ cooperated
with integrin to form a feedforward loop to induce integrin expression. In addition, TGFβ
activated integrin ligands, including vitronectin, fibronectin, laminin, and collagen. TGFβ was
also involved in the activation of integrin “inside-out” signaling. On the other hand, integrin can
regulate TGFβ activation. Integrin αvβ3 associates with TGFβ receptor II, and activates the
expression of TGFβ receptor I&II in lung fibroblasts. The latent form of TGFβ needs to be
cleaved to generate active TGFβ. Integrin αvβ3 acts as a docking site for MMP2 and MMP9,
which are the proteases responsible for latent TGFβ activation. In our study, TGFβ and PKM2
shared a similar PI3K pathway of activating myofibroblast differentiation.
If both TGFβ and PKM2 exist in the wound site at early time, it is interesting to ask
which one plays the major role in activating myofibroblast differentiation. In wound healing, the
major sources of TGFβ are from platelets and macrophage, whereas PKM2 is released from
neutrophils. Although the level of extracellular PKM2 at neutrophil infiltration peak can be very
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high, the activation of myofibroblast differentiation by TGFβ is still stronger due to its high
efficiency. If TGFβ is the major stimulator, then what is the role of extracellular PKM2? The
possible work flow could be that TGFβ and mechanical tension partially induces the
myofibroblast differentiation at early time of inflammation. High level of extracellular of PKM2
released from neutrophils interacts with integrin αvβ3 on the fibroblast surface which is induced
by TGFβ stimulation. This interaction further facilitates the differentiation process. Thus, TGFβ
can fully activate myofibroblast differentiation under the help of PKM2 activated integrin αvβ3
pathway.
In summary, our data demonstrated that extracellular PKM2 independently promoted
myofibroblast differentiation by activating integrins αvβ3 on cell surface of dermal fibroblasts.
In this regard, our discovery may uncover a new target that may help to develop therapeutic
strategies in facilitating wound repair. TGFβ is considered as the major stimulator which
activates myofibroblast differentiation that provides early collagen deposition and granulation
tissue formation. However, several studies have shown that TGFβ activation was not the only
one for myofibroblast differentiation. We suggested that release of PKM2 from activated
neutrophils at wound site replaced and strengthen the effect of TGFβ for myofibroblast
differentiation during wound healing.
6.3

Extracellular PKM2 prevents apoptosis of activated hepatic stellate cells during liver
fibrosis
Liver fibrosis is induced by chronic liver damage and inflammation. Neutrophils infiltrate

to the damaged area and release large amount of PKM2. To study the function of extracellular
PKM2 in liver fibrosis, we established a TAA/alcohol mouse model with rPKM2 after two and a
half weeks. The body weight was reduced in the TAA treated fibrotic mice, further decreased
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with addition of rPKM2. After TAA+rPKM2 treatment, both weight and size of liver were
increased compared with controls. Typical fibrotic feature was seen on the surface of those
livers. Serum marker screening showed that fibrosis induction by TAA/alcohol treatment
increased albumin, ALT and AST level in the blood. Addition of rPKM2 further increased serum
ALT and AST level. Sirius Red staining was used to examine the liver collagen contents.
TAA+rPKM2 treatment showed intensive collagen levels and thick collagen cross networks.
HSCs apoptosis is related to liver fibrosis progression. We found that TAA+rPKM2
treatment had increased α-SMA and reduced apoptosis that indicated function of extracellular
PKM2 in protecting HSCs from apoptosis. In vitro study showed that rPKM2 relieved the
apoptotic stress of HSCs and LX-2 cells from FasL and TRAIL induced apoptosis. rPKM2
interacted with integrin αvβ3 on the cell surface of activated LX-2 cells. Integrin αvβ3 activated
FAK, and PI3K to stimulate survival signal of HSC. Neutralization of extracellular PKM2 using
a specific antibody against PKM2 in TAA/alcohol liver fibrosis mouse model reduced liver
fibrosis progression. The collagen staining of IgGPK group showed less signal and very thin
collagen cross networks.
Our study revealed an unexpected role of extracellular PKM2 in facilitating liver fibrosis
progression by protecting activated HSCs from apoptosis. Reverse of liver fibrosis is the most
important task in the treatment of cirrhosis. HSCs apoptosis is a key to prevent progression of
liver fibrosis. Our results showed that antibody against PKM2 that disrupt the PKM2-integrin
αvβ3 interaction are very effective in reversing liver fibrosis in TAA/alcohol mouse model,
indicating a potential anti-fibrotic strategy and target.
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6.4

Physiological and pathological functions of extracellular PKM2
PKM2 is the enzyme acting at last step of glycolysis converting PEP to pyruvate. The

default function of PKM2 is same as other pyruvate kinases in glycolysis. However, the pyruvate
kinase activity of PKM2 is lower compared with that of other isoenzymes. PKM2 is expressed in
highly proliferating cells, suggesting a unique function related to proliferation. Slow glycolysis
rate caused by low pyruvate kinase activity of PKM2 results in the accumulation of
intermediated materials which in favor of proliferation. In the recent study, function of PKM2
involving in cancer cell proliferation was highlighted in cell nucleus. PKM2 translocates into
nucleus and acts as protein kinase to phosphorylate histone H3 and STAT3 to promote
proliferation. PKM2 also binds with HIF1 to regulate β-catenin.
PKM2 has two conformations existing in the cells, dimer and tetramer. Tetrameric PKM2
has higher affinity to substrate PEP and better pyruvate kinase activity, whereas dimeric PKM2
shows low pyruvate kinase activity due to weak affinity to PEP. In metabolic pathway, pyruvate
kinase catalyzes the last step of glycolysis by converting PEP to pyruvate and generating ATP.
This is the key connection between glycolysis and oxidative phosphorylation. In cancer cells,
PKM2 dimer with reduced pyruvate kinase activity holds glycolysis at the last step, and
facilitates the synthesis of intermediate metabolites for the need of proliferation. This is why
cancer cells develop the mechanism of alternative splicing to produce PKM2 over PKM1 in
favor of its metabolism (Mazurek, 2011).
In addition to the metabolic shifting role of PKM2 in the Warburg effect, PKM2
possesses an important relationship with HIF-1 and c-Myc which are two critical proteins in
metabolism pathway. PKM2 interacts with HIF-1α subunit and promotes activation of HIF-1
targeted genes. PHD3 enhances the interaction between PKM2 and HIF-1α. This indicates a
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positive feedback loop of PKM2 promoting HIF-1 transactivation and regulating metabolism in
cancer cells (Luo & Semenza, 2011). c-Myc was found to be the key regulator for the shift from
PKM1 to PKM2 in cancer cells. c-Myc upregulates the transcription of hnRNPA1 and hnRNPA2
to bind more to exon 9 (PKM1) in order to include exon 10 (PKM2) in the splicing result, thus
high PKM2/PKM1 ratio (David et al., 2010).
The study of PKM2 was focused in cytosol as a pyruvate kinase to regulate metabolism
or in cell nucleus as a protein kinase to promote proliferation. Extracellular PKM2 was
considered as diagnostic marker for diseases without any specific physiological or pathological
functions. Serum PKM2 level is used as diagnostic marker in several cancer cases, including
colorectal cancer, kidney cancer, gastric cancer, lung cancer, and cervical tumors. Our laboratory
discovered that extracellular PKM2 secreted by cancer cells promoted angiogenesis through
activation of integrin αvβ3 on endothelial cells. We also found PKM2 located extracellularly at
cutaneous wound site and in liver fibrosis. Neutrophil is another source of extracellular PKM2 in
addition to cancer cells. PKM2 was detected from blood circulation and stool samples in several
immune diseases, but the secretory pathway was not clear. PKM2 secretion is related with
exosome in cancer cells. In immune diseases, extracellular PKM2 was thought to be released by
dead immune cells. We discovered that PKM2 was released from activated neutrophils via
degranulation. Whether PKM2 is located in granules is still need to be examined.
In wound repair, macrophage is the dominant origin of secreting growth factors and
cytokines to activate angiogenesis and granulation tissue formation. Macrophages can influence
each phase of angiogenesis, including ECM rearrangement, endothelial cell proliferation and
migration, and capillary differentiation. TGFβ secreted from macrophage is considered the main
activator for myofibroblast differentiation. The classical concept of the connection between
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inflammation and proliferation stage is that neutrophils come first for cleaning, then
macrophages arrive later to finish cleaning and promote angiogenesis and granulation tissue
formation. We found that extracellular PKM2 released from neutrophils facilitated cutaneous
wound healing by promoting angiogenesis and fibrogenesis. This provides another aspect in
addition to the conception of macrophage activating proliferation stage. Neutrophils are
considered the early initiator of angiogenesis and fibrogenesis during wound repair. However,
extracellular PKM2 activated endothelial cell and fibroblast through integrin αvβ3, which is only
expressed after activation by TGFβ. It is not feasible for extracellular PKM2 from neutrophils to
activate angiogenesis and fibrogenesis before TGFβ from macrophages. Another possibility is
that small amounts of TGFβ are released from platelets early in wound repair and partially
activate endothelial cells and dermal fibroblasts. Large amounts of PKM2 released during
neutrophil infiltration enhance the activation and then together with TGFβ from macrophages to
further augment angiogenesis and fibrogenesis.
Given the fact that PKM2 is released from neutrophils, a key question is whether the
released PKM2 is dimer as released from cancer cells. Our lab previously demonstrated that
PKM2 translocates into cell nucleus and acts as a protein kinase to regulate gene transcription.
PKM2 dimer functions as a protein kinase, while the tetramer is a pyruvate kinase (Gao et al.,
2012). PKM2 is released from cancer cells and promotes angiogenesis. The released PKM2 is in
dimeric conformation and shows low pyruvate kinase activity compared with PKM1. The
dimer/tetramer ratio of PKM2 is also correlated with protein concentration (L. Li et al., 2014). In
cancer cells, the pathway of PKM2 release is still not well understood. Our preliminary data
indicated that the release of PKM2 is involved in the secretion of exosome and microvesicle. In
part two of this dissertation, we discovered PKM2 is released from neutrophil through
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degranulation, which is a similar secretory pathway as in exosome and microvesicle. Several
other reports revealed that PKM2 exists in the dimeric conformation upon different
modifications and mutations (Mazurek, 2007; Stetak et al., 2007). Therefore, we suspect the
released PKM2 from neutrophils is also in dimeric conformation. The cytosolic PKM2 should
still be tetramer. After modification such as phosphorylation or binding with other proteins,
PKM2 may dissociate from tetramer to dimer and further interact with the vesicle or granule
components during release.
In this dissertation, we revealed that PKM2 activated FAK-PI3K-PAK2 pathway through
integrin αvβ3 in dermal fibroblasts and leads to myofibroblast differentiation. This signal
pathway is independent of TGFβ-Smad pathway. Several factors have been shown to activate
myofibroblast differentiation without besides TGFβ, such as IL-6, NGF, Fizz1, angiotensin-II,
endothelin-1, and thrombin. However, the effect of TGFβ is not ruled out in those studies. We
used TGFβ antibody to neutralize TGFβ residue and TGFβ receptor antibody to inhibit TGFβ
signal pathway. rPKM2 still can induce expression of α-SMA in the previous two treatments.
This is a novel signal pathway of myofibroblast differentiation in addition to the classic TGFβ
one. Extracellular PKM2 can augment the TGFβ effect or even act alone when TGFβ is absence.
On the pathological side, we claimed that extracellular PKM2 released from activated
neutrophils protected activated HSCs from apoptosis that results in progression of liver fibrosis.
In HSCs, extracellular PKM2 activated PI3K signal pathway to stimulate the survival signal.
Currently, no effective treatment of reversing liver fibrosis/cirrhosis has been found. Most
studies are focused on the apoptosis of activated HSCs. Our results showed that specific PKM2
antibody that disrupts the PKM2-αvβ3 interaction is very effective in relieve liver fibrosis in
TAA/alcohol induced mouse model, indicating a potential anti-fibrosis strategy and target.

142

Compared to fibrosis in liver, the fibrosis progression is very similar in other tissue such as lung
and kidney. In the future study, we should test the function of extracellular PKM2 in other
fibrosis models.
6.5

Conclusions and Future Perspectives
In summary, extracellular PKM2 shares the same membrane target integrin αvβ3 on

different cell types and leads to different downstream pathways favoring to the function of cells.
As the similar proliferating function of nuclear PKM2 in cancer cells, extracellular PKM2 plays
a similar role of regeneration (angiogenesis and fibrogenesis) in wound healing. Extracellular
PKM2 acts as a cytokine or growth factor to activate endothelial cells and fibroblasts in favors of
regeneration. Release of PKM2 from activated neutrophils reveals the connection between
neutrophil infiltration and tissue regeneration. Nevertheless, in the pathological condition of
tissue regeneration, extracellular PKM2 acts as a double-edged sword. For example, when you
have an injury in liver, regeneration of liver undergoes the similar procedure as in the cutaneous
wound repair. Extracellular PKM2 functions as a supporter to heal injury. If injury persists,
chronic damage of the tissue leads to continuously influx of neutrophils to the injury site.
Accumulation of extracellular PKM2 becomes a destroyer by protecting HSCs from apoptosis.
Therefore, targeting extracellular PKM2 during liver fibrosis can be a valid method of pushing
HSCs to apoptosis, and finally reversing of liver fibrosis.
Currently, the study of PKM2 is divided into three parts. First, the canonical function of
PKM2 is to regulate metabolism in highly proliferating cells. Dimeric PKM2 catalyzes the last
step of glycolysis with rate limitation. Binding with FBP converts PKM2 to tetramer, and
enhances the pyruvate kinase activity of PKM2. The balance between PKM2 dimer and tetramer
is dynamically regulated (Dombrauckas et al., 2005). In cancer cells, to favor proliferation, the
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balance is more toward to dimeric PKM2 as a result of different modifications, including
phosphorylation of tyrosine 105 by tyrosine kinase, acetylation of lysine 305 by glucose
stimulation, and oxidation of cysteine 358 by ROS insult (Hitosugi et al., 2009; Lv et al., 2011).
The transition from tetramer to dimer PKM2 leads to an increased accumulation of metabolic
intermediates which support the proliferation of cancer cells. In order to inhibit cancer cell
proliferation and tumor growth, researchers aim on the discovery of PKM2 activator to drive the
conversion back to tetrameric PKM2. FBP and serine are the known allosteric activator of
PKM2.

Succinyl-5-aminoimidazole-4-carboxamide-1-ribose-5’-phosphate

(SAICAR)

also

regulates PKM2 allosterically (Keller et al., 2012). Two small molecules were identified in a
screen for PKM2 activator, thieno[3,2-b]pyridazinone (TEEP-46) and N,N’-diarylsulfonamide
(DASA-58). These to molecules functions similar to FBP to significantly increase the pyruvate
kinase activity of PKM2. They stabilize PKM2 in a tetramer conformation even with key residue
mutation such as K305 (Anastasiou et al., 2012).
Second, in addition to the original role of regulating glycolysis in cytosol, PKM2
translocates into the nucleus and functions as a protein kinase to promote cancer cell
proliferation. PKM2 can phosphorylate several protein substrates by using PEP or ATP as the
phosphate donor. The possible protein substrates include histone H3 on T11, STAT3 on Y705,
MLC2 on Y118, Bub3 on Y207, and ERK1 on T202. However, the molecular mechanism of this
protein kinase activity is still not clear. The function of nuclear PKM2 is involved with gene
expression and cell cycle progression. Nuclear PKM2 interacts with β-catenin and enhances the
transactivation activity of β-catenin to assist the phosphorylation of histone H3 by PKM2 (W.
Yang et al., 2011). PKM2 interacts with Oct4 and reduces the transcription activity of Oct4
which leads to the differentiation of glioma spheroids (Morfouace et al., 2014). PKM2 is also

144

involved in cell cycle and cytokinesis. PKM2 regulates G1-S phase transition by phosphorylating
Bub3. Aurora B can phosphorylate PKM2 on T45 to stimulate the phosphorylation of MLC2 by
PKM2. This phosphorylation together with Rho-associated protein kinase 2 (ROCK2) mediated
phosphorylation on S15 are critical in the process of cytokinesis (Jiang et al., 2014).
Third, PKM2 is found in extracellular space. Cancer patients have high level of PKM2 in
the blood serum. Serum PKM2 is used as an un-invasive diagnostic marker for cancer diagnosis.
Our laboratory discovered that the extracellular PKM2 is released from cancer cells.
Extracellular PKM2 interacts with integrin αvβ3 on the cell surface of endothelial cells and
promotes adhesion and migration. In this dissertation, we found PKM2 is also released from
neutrophils during inflammation. Extracellular PKM2 interacts with integrin αvβ3 on the cell
surface of both endothelial cells and fibroblasts. PKM2 activates integrin αvβ3 signaling
pathway to stimulate myofibroblast differentiation. Extracellular PKM2 also activates a survival
signal through integrin αvβ3 to protect activated HSCs from apoptosis and promotes liver
fibrosis. Overall, the original function of PKM2 is still in cytosol. After different modifications
or interacting with other factors, PKM2 tetramer converts to dimer, and then translocates into
nucleus or releases to the extracellular space.
The function of extracellular PKM2 is not well elucidated. Previously, we only knew that
it is correlated with tumor growth. In this dissertation, we observed that neutrophils or other
immune cells could be another source of extracellular PKM2. If we consider extracellular PKM2
as a cytokine using integrin αvβ3 as the cell surface receptor, then it is a connection between
neutrophil infiltration and angiogenesis/fibrogenesis. It helps us to better understand the function
of neutrophils during inflammation. We revealed that extracellular PKM2 promotes
myofibroblast differentiation independently of TGFβ. It indicates that neutrophil infiltration
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places a positive role in myofibroblast differentiation. Alternative PKM2- integrin αvβ3 pathway
can activate fibroblast without the involvement of the classical TGFβ-Smad pathway.
Extracellular PKM2 plays another important role during liver fibrosis. Everyone tries to find the
way to reverse liver fibrosis and focuses on activated HSCs as the target. We think extracellular
PKM2 could be the key modulator in liver fibrosis. Insult induces inflammation and activates
different immune cells. The activated immune cells release PKM2 and other cytokines to
promote differentiation of HSCs. PKM2, together with other growth factors, stimulates the
survival signal of activated HSCs and keeps them at the damaged liver tissue to induce a chronic
fibrotic status. We generated a specific antibody against PKM2 and tested it for liver fibrosis.
The fibrotic damage was well reduced and liver condition was partially reversed to the healthy
condition. The future study of extracellular PKM2 should be focused on its role in fibrogenesis.
Animal models with different types of tissue fibrosis should be studied to test the effect PKM2
antibody.
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SUPPLEMENTARY RESULTS
PKM2 translocates into cell nucleus and phosphorylates histone H4

Recombinant PKM2 used PEP as substrate to phosphorylate histone H4 at Serine 1 in
vitro. PKM2 translocated into cell nucleus at S and G2 phases which was correlated with histone
H4S1 phosphorylation.

